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Abstract 
 
Circulating tumor cells (CTCs) are the tumor cells shed from primary tumor, which enter 
the bloodstream and travel to distant anatomic sites to form metastasis. With emerging 
sensitive micro- and nanotechnologies, CTCs have been identified as blood-based 
biomarkers to guide cancer diagnosis and prognosis. Detecting CTCs, as a means of 
“liquid biopsy”, allows monitoring cancer progression in real time and predicting 
therapeutic response. The major challenge that limits the clinical utility of CTCs, 
especially in early stage cancer patients, is their rarity; specifically, there are only 1-10 
CTCs in one milliliter of whole blood. One way to overcome this critical limitation is to 
ex vivo expand CTCs through culturing. Previously, a few studies have shown limited 
success with CTC culturing from metastatic cancer patients.  
In this thesis, a microfluidic CTC capture device is optimized and tested for the capture 
and analysis of CTCs from lung cancer patients. A novel microfluidic co-culture model is 
developed to facilitate CTC expansion followed by downstream genomic, functional 
analysis and xenograft implantation. CTCs were isolated from more than 50 lung and 
esophageal cancer patients of various stages including patients with Stage I disease and 
cultured ex vivo. Using a 3D, on chip co-culture model, CTCs were successfully 
expanded in 70% of the patient samples. Cultured CTCs were characterized with 
immunostaining, RNA profiling, mutation analysis and invasion assays. We found 
concordant TP53 mutation in CTCs and matched primary tumors. Next-generation 
sequencing further revealed mutations in additional genes. 
It was found that, patients whose CTCs exhibited the greatest capacity to expand ex vivo 
had earlier recurrence. In one of the patient samples, expanded CTCs implanted in mice 
resulted in a xenograft tumor, demonstrating the expanded CTCs’ ability to metastasize. 
CTC-derived xenograft was compared with cultured CTCs and the primary tumor 
through IHC staining and RNA sequencing. We were able to demonstrate that the 
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xenograft had the same histology as the primary tumor. Genes related to EMT and tumor 
microenvironment were enriched in the xenograft. In addition, building upon this co-
culture model, CTCs from one of the ALK positive metastatic lung cancer patients were 
isolated and cultured. The cultured CTCs harbored the concordant EML4-ALK 
rearrangement as the tumor biopsy specimen and further served as an in vitro model for 
drug testing.   
Taken together, this study demonstrated that CTCs from early stage lung cancer are 
tumorigenic and mirror the phenotypic and genotypic status of primary tumors. Ex vivo 
culturing of CTCs changed the current paradigm of CTC research, and will make a 
significant impact in the era of personalized medicine. It will bring about opportunities 
for individualized drug screening, such as predicting treatment response to targeted 
therapies and the emergence of acquired drug resistance. Cultured CTCs will also serve 
as tools for understanding metastatic spread of cancer cells. 
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Chapter 1 
Introduction 
 
 
 
 
1.1 Motivation 
Circulating tumor cells (CTCs) are the lethal drivers of metastasis. They are tumor 
surrogates that carry relevant genomic and proteomic information of primary tumors. 
Sampling CTCs via blood drawn from peripheral veins can be non-invasive. It permits 
routine clinical monitoring and causes less pain than solid biopsy. Isolating CTCs has 
been a great challenge because of the low number of cells present in the bloodstream. To 
enhance the capture efficiency and specificity, microfluidic technologies have emerged to 
detect and analyze CTCs. Detecting and diagnosing cancer early in its progression 
increases survival. Isolating CTCs from early stage cancer patients will examine the 
potential of the cells to aid in early cancer detection. Furthermore, there is a need to 
increase the CTC number to expand the clinical utility of CTCs such as performing drug 
susceptibility testing and in vivo implantation. In this thesis, we aim to address this need 
by culturing CTCs ex vivo through a microfluidic co-culture model. 
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1.2 Microfluidics and CTCs 
1.2.1 Microfluidics for cancer research 
Microfluidics handles microliter volumes in microchannels of 1µm to 1000µm 
size. In such a regime, fluid flow is laminar, hence concentrations of molecules can be 
controlled [1]. Microfluidics was introduced as a biological tool in the early 1990s [2]. 
Since then, this interdisciplinary technology, known for manipulating reagents within 
miniaturized platforms, has been developing rapidly [3, 4]. The material used for 
preparing microfluidic devices has evolved from traditional silicon and glass, to 
elastomers rendering the device more biocompatible and of lower cost [1]. There are 
several inherent advantages of microfluidics, including reduced sample size and reagent 
consumption, short processing time, enhanced sensitivity, real-time analysis and 
automation [5]. One of the motivations for applying microfluidic techniques in life 
science is to automate the labor-intensive experimental processes similar to that 
accomplished in electronic circuits [2]. Polymerase chain reaction, electrophoresis on 
chip and DNA microarrays are among the earliest microfluidic ventures [2]. With a 
decade of development, microfluidic integrated systems are expanded to manipulate 
RNA, proteins and mammalian cells; and as biosensors, single cell assays for disease 
diagnosis and prognosis. Microfluidic devices are utilized to explore and investigate 
cancers in new and unconventional ways. 
Cancer research has long been at the forefront of medical and scientific research. 
Its seemingly incurable nature and large prevalence in society has made cancer a popular 
and well-funded area of research for decades. Cancer is a chronic disease involving 
multitude genetic alterations. It was estimated that in 2008, 12.7 million cancer cases and 
7.6 million cancer-related deaths occurred globally [6]. In 2011 in the United States alone, 
1.6 million people were newly diagnosed with cancers and 571,950 cancer-related deaths 
were projected. Prostate, breast, lung and colorectal cancers are the leading cause of 
cancer deaths in the US [7]. Since 2004, considerable funding has been allocated for 
technology advancement in search of more effective anti-cancer strategies [8].  
Traditionally, cancer diagnosis is highly dependent upon sampling tumor tissues 
or indirect quantification of proteins [9]. Often, these conventional sampling approaches 
are invasive, which lead to tissue damage, limited access and inability to get reliable 
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samples and cause high levels of patient discomfort.  Although proteomic and genomic 
research have identified a list of candidate cancer biomarkers in body fluids such as blood 
and saliva [10], there is still a lack of point-of-care devices for rapid and non-invasive 
diagnosis. Possible biomarkers in the blood include DNA, miRNA, proteins, serum 
microvesicles and circulating tumor cells (CTCs) [11-14]. However, these biomarkers are 
often present at low levels against massive background signals. For example, there are 
only 1-10 CTCs in 1mL of whole blood containing 106-107 blood cells [15, 16]; the ratio 
between targeted proteins versus the background is approximately 1:105 [17].  Given the 
challenge of detecting the actual signal from vast noises, researchers turn to MEMS 
(Microelectromechanical systems) based approaches. Inherently, microfluidics is suitable 
for analyzing complex fluids in vitro and thus offers a promising approach for cancer 
diagnosis and disease management [1]. In addition, because of the ease of manufacturing 
and low cost of microfluidic devices, biomarkers can be assessed routinely, which is 
essential for developing personalized medicine [18].  
1.2.2 Circulating tumor cells (CTCs) 
Circulating tumor cells (CTCs) are cells shed by underlying tumors and circulate 
in blood and lymphatic vessels. CTCs are the likely drivers of metastasis, which accounts 
for nearly 90% of cancer-related deaths [19]. They can ultimately lodge, invade and 
proliferate at distant organs initiating metastatic lesions (Figure 1). In some cancers, 
metastasis may occur in the early stage of tumor progression [20]. In addition, metastatic 
cells acquire mutations beyond those initiated within primary tumors [21].Therefore, 
detecting CTCs can be extremely valuable for cancer diagnosis in early stages and help 
with treatment decisions. 
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Figure 1. CTCs and the metastatic cascade. CTCs are the cells shed by the primary 
tumor, which enter the bloodstream, ultimately extravasate and form metastases in distant 
organs.  
 
1.2.3 Microfluidic technologies for isolating CTCs 
The emerging microfluidic technologies can isolate CTCs based on their 
biological or physical properties (Figure 2).  
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Figure 2. CTC isolation technologies. CTCs can be isolated based on their physical or 
biological properties. 
Immunoaffinity-based Isolation 
One of the major CTC isolation methods is based on antibody-antigen interactions. 
The most commonly used surface antigen is the epithelial cell adhesion molecule or 
EpCAM, first identified in the late 70’s [22]. EpCAM is overexpressed in breast, colon, 
lung, prostate, gastric, ovarian and renal carcinomas [22-24] and hence widely employed 
as the target in almost all immunoaffinity-based CTC isolation strategies.  
Early in 2004, CellSearch, demonstrated CTC-based diagnostic potential by 
separating CTCs using EpCAM-coated magnetic beads and correlating the number of 
isolated CTCs to prognosis in breast cancer patients. It is the only  device approved by 
the U.S. Food and Drug Administration for isolating CTCs in metastatic breast, colon and 
prostate cancers [25]. In the CellSearch system, blood specimens are fixed prior to CTC 
isolation. Although it can prolong the storage time of the blood samples, the available 
downstream analysis is limited because of the fixed cells.  
In 2007, Nagrath et al. reported a microfluidic-based CTC capture device, which 
was composed of 78,000 EpCAM-coated microposts embedded on a silicon chip [26]. 
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The chip can capture cancer cells from milliliters of unprocessed whole blood with high 
sensitivity and purity. The captured cancer cells were maintained in an appropriate 
condition for molecular analysis through immunostaining and RNA profiling. The chip 
successfully detected CTCs in all but one of 116 blood samples from 68 patients with 
metastatic lung, prostate, pancreatic, breast and colon cancer.  
Later in 2008, Maheswaran et al. showed that the CTC-chip technology 
monitored the epidermal growth factor receptor (EGFR) mutations in patients with non-
small-cell lung cancer (NSCLC). Sufficient DNA was isolated from the captured CTCs to 
allow allele specific assay testing and in few instances direct sequencing. Somatic genetic 
mutations were detected in 19 out of 20 EGFR positive patient samples. In addition, the 
secondary resistant mutations from 11 out of 12 patients, who developed resistance to 
tyrosine kinase inhibitors, were also shown [27]. This type of information, which is vital 
for diagnosis, prognosis, and therapeutics, was earlier provided only by repeated tissue 
biopsies. Non-invasive genotyping or “blood biopsies” provide possible alternatives.  
In 2010, Stott et al. developed an automated strategy to characterize CTCs of 
metastatic prostate cancer [28].  CTCs were stained for the prostate-specific antigen 
(PSA). The chip was imaged in a semiautomated fashion and CTCs were characterized 
by an image processing algorithm in terms of fluorescence intensity, cell shape and other 
morphological traits. This method enabled easier monitoring of CTCs in different patients 
during the course of therapy.  
The CTC isolation devices discussed so far immobilized antibodies on microposts 
through surface chemistry. In another approach, magnetic arrays coated with antibodies 
self-assembled in plain microchannels for CTC capturing [29].  This system was used to 
sort B-lymphocytes from patients with leukemia and lymphoma. In addition, cancer cells 
were separated from endothelial cells with an efficiency of 80% using the same device. 
Dharmasiri et al. demonstrated another immobilization technique using aptamers. This 
method captured prostate cancer cells with  high efficiency and purity [30]. Dickson et al. 
reported a streptavidin coated microfluidic device to isolate cancer cells from blood [31]. 
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Despite the ability to specifically target CTCs, challenges for CTC isolation 
remain. CTCs are very rare (1 to 10 per mL of whole blood) compared with billons of 
white blood cells and red blood cells. The rarity poses a significant engineering problem 
when designing a device to capture CTCs for high specificity, purity and  simultaneously 
keeping the cells viable for subsequent molecular analysis [15]. Researchers have been 
developing sophisticated microfluidic devices to address these issues.  
Stott et al. made a high-throughput polydimethylsiloxane (PDMS) based device 
with enhanced capture efficiency and optical properties [32]. The microchannel was 
fabricated into a herringbone shape, which generated passive mixing via microvortices. It 
can process larger volume of blood than the micropost-based CTC-chip while 
maintaining the same capture efficiency. For example, the herringbone chip 
maintained >40% capture efficiency at flow rate up to 4.8mL/hr but the efficiency of the 
CTC-chip dropped significantly above 2-3mL/hr.  After being captured, cancer cells were 
viable and intact for molecular characterization and imaging.  
Gleghorn et al. reported a geometrically enhanced differential immunocapture 
(GEDI) chip to capture prostate CTCs with high-efficiency and high-purity [33]. The 
researchers optimized the displacement, size and shape of posts to maximize the 
interaction between CTCs (15-25um) and the antibody coated surface while small blood 
cells (4-18um) can escape.  
Myung et al. demonstrated the immobilization of E-selectin and anti-EpCAM on 
the microfluidic channels for CTC isolation. E-selectin induced rolling of leukocytes and 
cancer cells at different velocities resulting in enhanced antibody accessibility to  cancer 
cells [34]. The cancer cells tended to roll faster as the shear stress increased while the 
rolling velocity of leukocyte remained stable. Therefore, this approach achieved 
separation of leukocytes and CTCs with increased cell capture efficiency.  
Dharmasiri et al. recently reported an integrated microfluidic system, which 
incorporated immunoaffinity-based capture, enzymatic release, conductivity enumeration 
and electrokinetic enrichment of colorectal CTCs [35]. This method allowed consequent 
manipulation and molecular profiling of CTCs using PCR coupled with a ligase detection 
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reaction (LDR) assay. Since this system contained an electrokinetic enrichment 
component, it can concentrate the mass-limited DNA samples extracted from CTCs. 
They were able to detect the KRAS mutation in the SW620 cell line but not in the HT29 
cell line, which was consistent with the known genotypes.  
Hoshino et al. utilized immunomagnetic separation mechanism to isolate cancer 
cells in a microchip. Blood samples containing spiked cancer cells were incubated with 
magnetic nanoparticles conjugated with anti-EpCAM prior passing through the device. 
This device can isolate as few as 5 cells per mL of blood  and can be operated at 10ml/hr 
flow rate without a significant reduction of capture rate [36]. 
Most recently, Kang et al. presented a novel CTC isolation approach which 
incorporated magnetic separation with microfluidic devices that permitted removal of 
captured CTCs from the device followed by culturing [37]. The device consisted of a 
main channel flanked by two rows of dead-end side chambers for CTC collection. One 
mouse blood sample was first treated with EpCAM coated magnetic beads followed by 
flowing through the isolation channel. After that, CTCs can be released by moving the 
magnet to the opposite side of the device. CTCs were then cultured and checked for 
viability.  
The major drawback of immunoaffinity-based isolation is that the EpCAM 
expression level on CTCs varies. Some of the CTCs might not express EpCAM, 
particularly cells that undergo the epithelial-mesenchymal transition(EMT) [38]. 
Therefore, immunoaffinity approaches miss subpopulations of CTCs, which may carry 
important molecular information about primary tumors. Utilizing size-based separation 
and filtration in addition to immunoaffinity methods could increase the yield with 
minimal loss of low/none EpCAM expressing cells.  
Size-based biomarker independent Separation  
CTCs are often  larger in size and may have a different specific gravity than blood 
cells therefore they can be separated from blood cells either by physical filtration or by 
hydrodynamic forces [39]. One advantage of the size-based separation is that cells can be 
enriched without using a specific antibody. With hydrodynamic separation, there is an 
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added advantage that the system can be operated at a relatively high flow rate, which is 
valuable to enriching rare CTCs. Furthermore, isolated CTCs can be collected without 
compromising cell viability or genetic contents thereby enabling off-chip cellular and 
molecular characterizations. Microfluidic devices enable sorting of CTCs based on size 
followed by single cell analysis and culturing. 
Zheng et al. presented an efficient membrane microfilter device made of 
parylene-C for isolating prostate cancer cells from whole blood [40]. The membrane filter 
contained 16,000 evenly distributed pores of 10µm diameter with 20µm space in between. 
The membrane was integrated with electrodes for direct electrolysis of the retained 
cancer cells followed by the polymerase chain reaction (PCR). Later, researchers used 
two-layer membranes to filter viable prostate and breast cancer cells [41]. The captured 
cells were cultured on device for 2 weeks. Two issues arose with increasing volumes of 
blood processed: the membrane was easily clogged and whole blood needed to be diluted 
before filtering. 
Kuo et al. demonstrated a microfluidic filtration system which separated breast 
cancer cell spiked into whole blood with 50-90% recovery rate [42].  The device 
consisted of a serpentine channel interconnected with two outer filtrate channels with 
rectangular apertures. The force experienced by cells during the filtration process was 
carefully assessed and the dimensions of the apertures were adjusted accordingly to 
minimize cell damage. 
Hur et al. presented a device to enrich cancer cells in diluted blood by a factor of 
5.4 [43]. Inertial lift forces and viscoelastic forces created distinct focusing positions of 
deformable particles in microchannels having high aspect ratios. Despite high-throughput 
and ease of operation, blood samples needed to be diluted to avoid defocusing caused by 
cancer and blood cell interactions. 
Lim et al. utilized a particle tracking analysis (PTA) method to study the particle-
focusing in microchannels [44]. Polystyrene beads, white blood cells and prostate cancer 
cells (PC-3) were tested in both diluted and whole blood. Two-dimensional focusing 
profiles were generated as guidelines for isolating CTCs.  
10 
	
Despite some key advantages of the size-based separation, the performance of this 
technique is still limited with heterogeneous sizes and morphologies of CTCs [45]. To 
overcome this challenge, additional downstream processes are needed to increase 
detection accuracy and sensitivity.   
Other MEMS based Methods  
Talasaz et al. demonstrated a magnetic sweeper utilizing an immunomagnetic 
mechanism [46]. The device used magnetic rods to sweep wells of a six-well plate to 
isolate magnetically labeled breast cancer cells from blood. The cells were released and 
were analyzed by genomic sequencing and other molecular assays. Moon et al. combined 
both hydrodynamic focusing and dielectrophoresis to isolate cancer cells with high flow 
rates [47]. Diluted blood was passed through a multi-orifice microchannel. Blood cells 
and cancer cells held different equilibrium positions in the stream to facilitate cell 
separation. Cancer cells, now pooled with fewer blood cells were then flowed into a non-
uniform electric field for further separation. The combined modules achieved efficient 
enrichment of cancer cells in a short period. Chen et al. presented a microfluidic disk to 
negatively deplete non-tumor cells via immunomagnetic principles [48]. Non-targeted 
cells were labeled with magnetic beads. As samples passed through a multistage 
magnetic field, the labeled cells were trapped. Compared with the positive selection 
methods, negative depletion accommodates the need to capture CTCs, which don’t 
express known surface markers [49].  
 
List of Technology Principle Application Clinical Study     
CTC-chip [26] Immunoaffinity 
 
Isolation of CTCs 
(1ml/hr flow rate,60-65% 
efficiency,50% purity from 
patient samples) 
68 patients with 
metastatic lung, 
prostate, pancreatic, 
breast and colon 
cancer 
    
CTC-chip [27] Immunoaffinity 
 
Identify EGFR mutations 27 patients with 
metastatic non-small-
cell lung cancer 
    
CTC-chip [28] Immunoaffinity 
 
Automated imaging of 
captured CTCs 
62 patients with 
prostate cancer 
    
CEE microchannel [31] Immunoaffinity Isolate of cancer cells from 
blood cells 
N/A     
Herringbone-chip 
[32] 
Immunoaffinity 
 
High-throughput mixing and 
isolation of CTCs 
(1.5-2.5ml/hr flow rate, 90% 
15 patients with 
metastatic prostate 
cancer 
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efficiency, 14% purity from 
spiking cells in blood) 
Self-assembled 
magnetic arrays 
[29] 
Immunomagnetic Isolation of B-lymphocytes 
(9ul/hr flow rate, 94% yield) 
7 patients with B-cell 
hematological 
malignant tumors 
(leukemia and 
lymphoma) 
    
Aptamer selection chip 
[30] 
Immunoaffinity 
through aptamers 
Isolation of prostate cancer 
cells from blood ( 2ml/hr 
flow rate, 90% recovery, 
100% purity—cell line test) 
N/A     
Geometrically enhanced 
differential 
immunocapture (GEDI)  
chip [33] 
Immunoaffinity 
 
Isolation of prostate cancer 
circulating tumor cells 
(1ml/hr flow rate, 85% 
efficiency, 68% purity from 
spiking cells in blood) 
Blood samples of 
castrate-resistant 
prostate cancer 
patients 
    
E-selectin biomimetic 
chip [34] 
Immunoaffinity & 
Biomimic 
Isolation of cancer cells from 
mixture of leukocytes 
(1.2ml/hr flow rate, 35% 
efficiency) 
N/A     
Integrated CTC 
selection chip [35] 
Immunoaffinity & 
electrokinetics 
Isolation, enumeration, 
enrichment of CTCs 
( 1.5ml/hr flow rate, 96% 
efficiency) 
PCR/LDR detection of 
KRAS colorectal cancer cell 
mutations 
N/A     
Immunomagnetic chip 
[36] 
Immunomagnetic 
Nanoparticles 
Capture cancer cells spiked in 
blood 
N/A     
Micromagnetic chip 
[37] 
Immunomagnetic Isolation CTCs and release 
for culturing (90% efficiency) 
N/A     
Membrane microfilter 
[40, 41] 
Size Separation of cancer cells 
from blood (89% recovery) 
N/A     
Filtration chip [42] Size & 
Deformability 
Separation cancer cells from 
blood cells (0.72-0.96ml/hr 
flow rate 50-90% recovery,) 
N/A     
Deformability-based 
chip [43] 
Size & 
Deformability 
High-throughput separation  
and enrichment of CTCs 
from diluted blood (1.5-
27ml/hr flow rate, 96% yield, 
3.2-5.4 fold enrichment) 
N/A     
Particle focusing chip 
[44] 
Size Use particle trajectory 
analysis to study cancer cell 
focusing in whole blood 
N/A     
MagSweeper [46] Immunomagnetic Isolation and enrichment of 
breast cancer cells from 
whole blood (process 9ml 
blood per hour, 62% 
efficiency, 51% purity) 
Blood samples from 
17 female patients 
with metastatic breast 
cancers 
    
MOFF and DEP chip 
[47] 
 
Size and 
Dielecrophretic 
properties 
Isolation of breast cancer 
cells from blood (126ul/min 
flow rate, 99% efficiency) 
N/A     
Negative selection disk 
[48] 
Immunomagnetic Isolation of breast cancer 
cells from mononuclear cells 
mixture (60% yield) 
N/A     
Table 1. Microfluidic technologies for isolating CTCs 
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1.3  Current Status of CTCs as liquid biopsy in lung cancer 
CTCs have garnered a lot of attention in the past few decades. Isolation of these 
rare cells from the billions of blood cells has been a challenge until recent times. With the 
advent of new sensitive technologies that permit live cell isolation and downstream 
genomic analysis, the existing paradigm of CTC research has evolved to explore clinical 
utility of these cells. CTCs have been identified as prognostic and pharmacodynamic 
biomarkers in many solid tumors, including lung cancer. As a means of liquid biopsy, 
CTCs play a major role in the development of personalized medicine and targeted 
therapies. The following part of the chapter discusses the state of various isolation 
strategies, cell separation techniques and key studies that illustrate the application of 
liquid biopsy to lung cancer.  
1.3.1 Background 
Lung cancer is the leading cause of cancer worldwide, accounting for 160,000 
deaths in the United States in 2014 [50] with a 5-year survival rate of 20% [51].  
Approximately 224,000 new cases of lung cancer were reported in 2014 [51]. Smoking is 
the leading risk factor [52]. Non-small-cell lung cancer (NSCLC) constitutes 80% of all 
new lung cancer cases [53]. Over 50% of patients are diagnosed initially with locally 
advanced or metastatic disease with worse outcomes. Surgically resectable Stage I-III 
non-small cell lung cancer (NSCLC) constitutes 25% of all lung cancers [54]. Despite the 
performance of seemingly “curative” surgery for locally confirmed disease in these 
patients, more than 50% will recur in 5-years and succumb to the disease [55]. Survival is 
improved through screening, early diagnosis and treatment [56]. However, currently 
approved screening strategies involving low dose CT scans have a low sensitivity and 
high false positive rates of >90% [56]. There is an unmet need for additional biomarkers 
that can improve the sensitivity of low dose CT screening, particularly in patients with 
indeterminate pulmonary nodules. Following a diagnosis of lung cancer and stage 
specific therapy, currently, the only available techniques to monitor disease progression 
other than clinical symptoms, are periodic CT scans done every 3-6 months. Earlier 
detection of recurrence in cases of earlier stages of lung cancer (Stage I and II) is needed 
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to direct certain subsets of patients for treatment of oligometastatic disease; this may 
include surgery and/or radiation therapy. In cases of patients with more advanced lung 
cancers, surveillance CT scans may demonstrate progression of disease; repeat biopsies 
of these recurrent/progressive lesions allow us to determine the underlying resistance 
mechanisms, in cases of lung cancers associated with specific molecular targets [57]. 
This type of surveillance may miss early recurrence/resistance and identification of 
treatable oligometastatic disease. In addition, repeat biopsies are invasive and not without 
risk. There is an unmet need for earlier detection of resistance in this subgroup of patients 
using a minimally invasive approach, which could potentially serve as decision aid for 
subsequent alternative therapies targeting secondary mutations or alternative pathway 
activation [58, 59]. Furthermore, a better non-invasive approach for serial monitoring is 
necessary to address other clinical and research unmet needs, not only for early response 
assessment for targeted therapies, but also for novel immunotherapies where radiologic 
response may lag behind or be erroneous (e.g.: pseudo-progression).   
Emerging research in blood-based biomarkers provides new opportunities to 
diagnose lung cancer earlier and to assist with detection of earlier recurrence. These 
biomarkers include circulating tumor cells [60] and circulating cell free nucleic acids 
(CfNA) [61-63]. CfNA are released from apoptotic or necrotic tumor cells [64]. Besides 
plasma, tumor nucleic acids have also been detected in other fractions of blood, such as 
platelets [65], extracellular vesicle exosomes [66], and buffy coat (leukocyte-enriched) 
[67]. New technologies are being developed to increase the sensitivity and specificity of 
cfNA detection in the blood [68]. Circulating tumor cells (CTCs), on the other hand have 
been extensively studied as prognostic and pharmacodynamic biomarkers in many 
cancers [69-73]. Both cfNA and CTCs were demonstrated to correlate with tumor burden 
and revealed genetic signatures of primary and metastatic tumors [27, 74]. CTC 
processing technologies however, have unique advantages over cfNA, by permitting a 
vast array of molecular and functional studies including cell culture, xenograft 
implantation, and ex-vivo drug testing (Figure 3) [75]. CTCs represent a subset of tumor 
cells that have acquired the ability to disseminate from the primary tumor and intravasate 
to the circulatory system [76].  CTCs may be a viable non-invasive alternative to tissue 
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biopsies for diagnosis of lung cancers. In many patients, however, CTCs are quite low in 
number, and they need to be isolated from an overwhelming majority of blood cells (1 
CTC: 1 billion blood cells). We have reported capability of detecting and characterizing 
CTCs from early stages lung cancer [77]. CTCs have demonstrated utility in surveillance 
of patients and their changing numbers predict PFS and OS in several cancers [45, 70]. 
Additionally, CTCs have been proposed as surrogate biomarkers in a multitude of 
research areas, including the selection of neoadjuvant and adjuvant therapy, detection of 
recurrent disease and as pharmacodynamic biomarkers of novel therapeutics [73, 76, 78-
83]. We summarize current technological and scientific advancements in CTC research 
specifically pertaining to lung cancer (Figure 4).  
  
Figure 3. Liquid biopsy of lung cancer. Different aspects of using CTCs as surrogate 
biomarkers in lung cancer. 
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Figure 4. Application of CTCs in lung cancer. a. Less than 5 CTCs/7.5ml of blood 
predict improved survival by CellSearch system [70]. b and c. Higher numbers of CTCs 
are detected in metastatic lung cancer than cancer without distant metastasis [84]. d. 
NSCLC CTCs are detected by ISET technology and stained positive for EGFR [85]. e. 
NSCLC CTCs isolated by CellSearch system are stained positive for EGFR and CK [82]. 
f. Morphologic features of NSCLC CTCs [86]. g. CTCs detected by HD-CTC assay are 
stained positive for CK (red) and negative for CD45 (green) [87]. h and i. Mutations 
detected in CTCs, primary tumors and metastatic sites. Copy number variation patterns 
among single CTCs, primary tumor and metastatic sites [88]. j. ALK rearrangements in 
CTCs and primary tumor [89]. k and l. ALK rearranged CTCs are stained positive for 
vimentin (k) and N-Cadherin (l) [89]. m. ROS1-rearranged CTCs are compared to 
primary tumor[90]. n. CTCs isolated from SCLC patients generate xenografts [91]. o. 
CTC-derived xenografts are stained for different protein markers [91]. p. NSCLC CTCs 
are isolated and expanded by a microfluidic co-culture model and stained positive for CK 
[77]. 
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1.3.2 CTC isolation technologies demonstrated in lung cancer 
CTCs have now been proposed as surrogate biomarkers in over 270 clinical trials 
[61].  However, to date, CTCs have not been incorporated into routine clinical practice 
for management of patients with cancer. The efforts to identify biological relevance and 
clinical utility of CTCs parallel the development of CTC isolation technologies. There are 
several key parameters worthy of consideration when designing a method to isolate CTCs: 
a) specificity, b) sensitivity, c) purity, d) viability, e) throughput. All the downstream 
assays such as molecular and genomic analysis and culturing for ex vivo drug testing 
depend on these factors. We will discuss about pros and cons associated with current 
isolation technologies generally and specifically as they pertain to lung cancer (Table 2).  
Technology Approach Flow 
rate 
mL/h
r 
Recover
y cell 
lines  
Purity 
WBCs/m
L 
Patient 
samples 
 
Whole 
blood 
Genomi
c 
analysis 
Liv
e 
cell
s 
Cultur
e 
Drug 
testin
g 
Cell Search EpCAm coated 
magnetic 
beads 
 
NA >80% Low < 50% in 
breast [92] 
32% in 
lung 
cancer, 
5CTCs/7.5
ml [70] 
N N N N N 
Epic 
Sciences 
No 
enrichment, 
RBCs lysed 
blood 
deposited on 
slides 
NA NA None  73% in 
lung 
cancer 
[87], 55% 
in 
melanoma 
[93] 
N Y, single 
cell for 
copy 
number  
N N N 
Mag 
Sweeper 
Flow through 
immunomagne
tic capture 
 62% ± 
7% 
 
 100% in 
metastatic 
breast 
cancer, 
12CEpCs/9 
mL [94] 
Y, 
need 
dilutio
n  
Y Y N NA 
ISET Size based 
filtration 
NA One 
CTC per 
1ml of 
blood 
NA 80% in 
lung 
cancer [85, 
89, 95] 
N Y, FISH N N N 
CTC iChip Size based 
separation +ve 
or –ve 
selection with 
mag beads 
9.6 > 95% 
for –ve 
78%-
98% for 
+ve 
>10,000 
for –ve  
<10,000 
for  +ve 
90%  from 
multiple 
types of 
metastatic 
cancers  
including 
lung 
cancer [96] 
Y, not 
a 
single 
step 
Y, single 
cell 
RNA 
expressi
on 
Y Y Y 
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Table 2. Comparison of CTC isolation technologies pertaining to lung cancer 
Collectively, there are two major approaches; one is anti-epithelial cell adhesion 
molecule (EpCAM) dependent while the other is EpCAM independent. The FDA 
approved CellSearch technology utilizes EpCAM coated magnetic beads to isolate CTCs 
in a multitude of cancers in spite of limited detection efficiency (32% in lung cancer) [70, 
92, 101, 102]. Microfluidic-based technologies have changed the existing paradigm for 
recovery of CTCs. Microfluidic chips coated with EpCAM and microfluidic systems 
utilizing immunomagnetic principles have been shown to capture CTCs from lung cancer 
samples with 100% efficiency [26, 100, 103, 104]. These antibody-based microfluidic 
devices have the advantages of high sensitivity, low numbers of white blood cells 
contamination (can be as low as 1500 WBCs), as well as preserving the viability of CTCs 
due to minimal handling of whole blood. The drawbacks are that they suffer from limited 
throughput due to low flow rates (1-3 ml/hour) and a requirement for antibody-antigen 
interaction. Another problem with EpCAM dependent methods is that they can only 
capture a subset of CTCs and miss cells undergoing the epithelial-mesenchymal 
transition (EMT) [61]. Wit et al. recovered lung CTCs by filtration from the waste of 
CellSearch system [105]. The percentage of patients having more than 5 cells per 7.5ml 
of blood increased from 15% (EpCAM positive) to 41% (EpCAM positive and negative). 
This suggests that including the EpCAM negative population increases CTC recovery. 
FACS 
Sorting 
Surface marker 
based selection  
Very 
Low 
NA Very 
Low 
<10%  [97] Y Y Y Y N 
RosetteS
ep kit 
Depletion of 
WBCs 
NA NA NA NA [91, 
98, 99] 
multipl
e steps 
Y Y Y NA 
CTC 
chip 
Positive 
selection 
1 >95% NA 72% in 
lung 
cancer [77] 
Y Y Y Y N 
GO Chip Nano pillars 
with Graphene 
Oxide 
1-3 > 95% 
2-5 
CTCs 
<1000 > 95% 
sensitivity, 
10CTCs/m
L [100] 
Y Y Y Y N 
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In contrast, the label-free approaches for isolating CTCs do not rely on the 
expression of specific cell surface markers but instead on inherent CTC properties such 
as size, deformability, or dielectric susceptibility, and/or negative selection of WBCs [41, 
106-114].  While improvements in size-based and other physical separation techniques 
have allowed higher throughput over the years, they suffer from limitations related to 
heterogeneity of tumor cells, contamination with blood cells and result in lower yield and 
specificity compared with the antigen-based systems [115]. For example, CTCs within a 
patient may have a wide range of sizes (>4 to 30 µm) and many of them may overlap in 
size with blood cells [116]. More recently, several new integrated platforms have 
emerged for CTC isolation. Liu et al. introduced an integrated device that separated 
blood cells and CTCs by deterministic lateral displacement followed by an affinity-based 
enrichment (9.6 ml/hour) [117]. The CTC-iChip by Ozkumur et al. combined magnetic 
labeling and high-throughput sorting of cells (8 ml/hour) [96], which was based on the 
principle of conjugating capturing antibodies on magnetic particles and enriching rare 
cells by applying external magnetic forces [118]. While EpCAM independent systems 
allow high throughput and an unbiased, surface-marker independent approach, which can 
capture cells undergoing EMT [119], the need for multiplexing and pre-processing of 
blood samples makes it cumbersome and time consuming. Chang et al. employed similar 
principles by labeling CTCs with antibody cocktail conjugated with magnetic beads 
followed by size-based filtration to trap CTCs on chip for immunofluorescence staining 
[120]. This system also operated at high flow rates (2ml/min) but required RBC lysis and 
the average WBC contamination was around 4000.  
Other label-free technologies, which are not microfluidic based, are also 
employed in clinical evaluation of lung CTCs. The ISET (isolation by size of epithelial 
tumor cells) technology, isolating CTCs based on their larger size, is among the earliest 
EpCAM independent approaches which filter CTCs from blood cells as they pass through 
a membrane filter [95]. CTCs were detected in 80% of samples from stages IIIA to IV 
NSCLC patients using ISET compared with 23% using CellSearch [85]. Using the same 
approach, CTCs were present in 65% of NSCLC patients in a more recent report [121]. In 
another study, an automatic microscope scanning and analysis technology called high-
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definition CTC (HD-CTC) assay was utilized to examine CTCs from stage I to IV 
NSCLC patients [87, 122]. This technology permitted high-resolution imaging of CTCs 
and was not biased towards size or surface markers. Recently, DNA aptamers were 
utilized to isolated CTCs from NSCLC patients [123]. CTCs were identified in 86% of 
the samples that were positive to aptamers and pan-CK. The ISET, HD-CTC assay and 
aptamer approach require RBC lysis and have limited purity of isolated CTCs, therefore 
posing constraints on molecular and functional studies of the cells.  
In summary, CTC technologies have evolved rapidly over the last decade, yet 
there is none that has FDA approval other than CellSearch. However, to incorporate 
CTCs into basic as well as small cohort clinical research, there are more tools than ever 
before, with microfluidic devices leading the way with higher sensitivity. Any ideal CTC 
technology should offer high throughput, minimal handling (whole blood) that can 
separate live CTCs with high sensitivity and specificity. Presently, there is no single 
technology that is optimal for every downstream analysis; the choice of technology is 
driven more by the end user application and ease of accessibility to the technology. 
Immunoaffinity-based technologies offer both sensitivity and specificity albeit with 
dependence on the known biomarkers. A high-throughput system that requires minimal 
pre-manipulation of whole blood and that can operate with either positive selection or 
negative depletion approach seems to be most promising for lung cancer CTC isolation. 
Furthermore, the efficiency of positive selection depends on the discovery of lung cancer 
specific surface markers such that a cocktail of capturing antibodies can be applied to 
target a broader range of lung CTCs.  
1.3.3 CTCs as prognostic and predictive markers in lung cancer 
Previously, the oncology community believed that there was little merit in 
diagnosing recurrence or progression earlier in patients who had surgery for earlier stages 
of lung cancer or following initial therapy for locally advanced /metastatic NSCLC. This 
was related to poor therapy choices at recurrence/progression that often did not alter 
clinically significant outcomes such as progression free survival (PFS) and overall 
survival (OS). There has been a re-think of this approach in a small but significant 
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minority of patients. This relates to the emerging field of therapy directed at 
oligometastatic disease such as local radiation or use of immunotherapy or newer 
biologics that may render patient disease free for a significant amount of time, even if 
overall survival is not affected. Many of these therapies are also better tolerated with 
broader therapeutic windows. We will outline various studies relating CTCs to prognosis 
in lung cancer as well as studies that predict therapy response. 
Hofman et al. used ISET technology to isolate CTCs from 208 NSCLC patients 
with stages I to IV cancer. Fifty percent of these patients had CTCs by morphological 
examination [86]. A cut-off value of >50 corresponded to shorter progression-free-and 
overall survival (PFS and OS). There was however, no direct correlation between 
numbers of CTCs and disease stage, or other clinicopathologic parameters. Therefore, 
CTCs and tumor staging appeared to be independent prognostic factors. In another study 
using the CellSearch system, there were greater numbers of CTCs in metastatic lung 
cancer patients (P<0.001) compared to patients without distant metastases [84]. Similarly, 
another study using the CellSearch system found that in 101 patients with Stage III/IV 
NSCLC, numbers of CTCs were higher in stage IV compared to stage III patients [70]. 
With a threshold of 5 CTCs in 7.5 ml blood, patients were categorized into favorable and 
unfavorable groups. Both the PFS (6.8 v 2.4 months) and OS (8.1 v 4.3 months) were 
higher in the favorable group than the unfavorable (P<0.001). Additionally, CTC 
numbers decreased with one cycle of chemotherapy. Reduction in numbers of CTCs with 
therapy correlated with improved PFS (6.9 v 2.4 months; P=0.005) and OS (8.8 v 3.9 
months; P<0.001). This study highlights that CTC numbers are not only prognostic, but 
also that a change in CTC number with therapy predicts disease progression dynamically.   
Dorsey et al. investigated the change of CTC number in patients with localized 
NSCLC undergoing radiation treatment. Using a telomerase-based detection assay, 65% 
of the patients were positive for CTCs prior to treatment. CTC numbers significantly 
reduced after radiation (9.1 CTCs per ml v 0.6 CTCs per ml; P<0.001). This study 
suggested analyzing CTC could serve as “real-time liquid biopsies” accompanying 
treatment to monitor tumor progression [124].  Several studies examining CTCs in 
advanced NSCLC patients receiving chemotherapy showed that >2 CTCs/7.5mL or any 
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increase in CTC numbers after therapy predicted lower OS and PFS (P=0.05) [82, 83, 
125]. To improve detection sensitivity, CTCs from pulmonary vein blood were examined 
in patients undergoing surgery [126-128]. Compared to peripheral CTCs (2 out of 30 
positive), pulmonary CTCs were present in 22 out of 30 samples before surgery (0-1122 
cells/2.5ml, median, 4 cells/2.5ml) [127]. Surprisingly, the number of pulmonary CTCs 
increased significantly after surgical manipulation (0-1855 cells/2.5ml, median, 60 
cells/2.5ml); this increase also correlated with pathological evidence of microscopic 
lymphatic invasion (P=0.043). Chudasama et al. investigated the effect of endobronchial 
cryotherapy on shedding of CTCs before and after the procedure in peripheral blood 
[129]. CTC count increased following cryotherapy in 15 out of 20 advanced stage 
patients (P=0.0086), which predicted poor prognosis during follow-up. In summary, these 
studies suggest that monitoring change of CTC numbers during therapy is prognostic for 
NSCLC. An increase of CTC counts may entail additional follow-up examinations.  
More recently, several groups reported on the prognostic value of CTC clusters 
called circulating tumor microemboli (CTM) [85, 122]. Krebs et al. observed the 
prevalence of CTM by ISET technology in 43% of patients with stage IIIB/IV NSCLC 
[85]. In another study using HD-CTC assay, 50% of NSCLC patients with stage I to IV 
disease had CTM [122]. It was shown CTM can be used to diagnose lung cancer when 
combined with clinical and imaging data. CTMs were also observed in pulmonary venous 
blood of NSCLC patients [128]. Among 130 patients tested, 74% of them were positive 
for CTCs. CTM were detected in 33% of samples which predicted tumor recurrence and 
worse disease-free survival rate (P<0.01).  
Other studies correlated prognosis to the presence/absence of protein expression 
of CTCs in NSCLC. As demonstrated by Wu et al., CTCs in multiple types of cancer 
including lung cancer harbored a mixed population of epithelial and mesenchymal 
phenotypes [130]. Nel et al. stained CTCs for both epithelial markers such as EpCAM 
and pan-cytokeratin (CK) as well as mesenchymal markers such as N-cadherin and 
CD133 [131]. Different subsets of CTC populations were identified with heterogeneous 
combinations of epithelial and mesenchymal characteristics. CD133 expression 
correlated positively with N-cadherin. The presence of these mesenchymal markers 
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predicted shorter PFS (2 vs 8 months, P=0.003) likely due to emergence of 
chemoresistant populations.  
Small cell lung cancer (SCLC) accounts for 13% of newly diagnosed lung cancer. 
It is considered aggressive with early dissemination and poor prognosis [132]. Hou et al. 
demonstrated that CTCs were present in 85% of SCLC compared to 21% in NSCLC 
patients [70, 133]. Higher CTC numbers were noted in SCLC than NSCLC; > 50 
CTCs/7.5ml of blood predicted shorter PFS (4.6 months vs 8.8 months; 95% CI) and OS 
(5.4 months vs 11.5 months; 95% CI). A reduction in CTC number after chemotherapy 
was associated with longer PFS (9.6 months vs 4.1 months; 95% CI) and OS (10.4 
months vs 4.1 months; 95% CI). Huang et al. evaluated prognostic significance of CTCs 
in SCLC. CTCs were enumerated before and after chemotherapy [134]. A reduction of 
CTCs was observed in 16/26 patients after treatment. However, CTC count at baseline 
and the percentage change of CTCs was not statistically significantly associated with 
survival. A summary of the studies investigating the prognostic value of CTCs in lung 
cancer is shown in Table 3.  
Study Technology Sensitivity 
(% of patients 
positive for CTCs) 
Prognostic significance 
Hofman et al.  [86] 
208 NSCLC patients 
Stage I to IV 
ISET 50%  > 50 CTCs corresponded with shorter OS 
and PFS 
Tanaka et al. [84] 
125 lung cancer 
patients 
Stage I to IV 
25 patients with 
nonmalignant diseases 
CellSearch 30%  in all patients 
71% in metastatic 
patients 
CTC count was higher in lung cancer than 
nonmalignant patients. CTC count was 
higher in patient with distant metastasis.  
Kreb et al. [70] 
101 NSCLC patients 
Stage III to IV 
CellSearch 21% at baseline 
(32% at Stage IV, 7% 
at Stage IIIB) 
> 5 CTCs/7.5ml blood predicted shorter 
PFS and OS. A reduction in CTC count 
after chemotherapy predicted improved 
survival.  
Dorsey et al. [124] 
30 NSCLC patients 
received radiation 
therapy 
 
Telomerase-based 
assay  
65% before RT 
 
CTC count decreased in patients 
responding to to RT.   
Juan et al. [125] 
37 NSCLC patients 
Advanced stage (IIIB-
IV) 
CellSearch 24% at baseline No significant prognostic conclusion was 
made 
Muinelo-Romay et al. 
[83] 
43 NSCLC patients 
Stage IIIB and IV 
CellSearch 42% at baseline > 5 CTCs/7.5ml blood at baseline 
predicted shorter PFS and OS. CTC count 
increase during chemotherapy correlated 
with worse PFS and OS.  
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Punnoose et al. [82] 
41 NSCLC patients  
Advanced stage  
CellSearch 76% at baseline Reduction in CTC count after 
chemotherapy predicted longer PFS.  
Sienel et al. [126] 
62 NSCLC patients 
Stage I to III 
Ficoll-Hypaque  
Centrifugation 
18% in pulmonary 
venous (PV) blood 
Presence of CTCs in PV blood was 
associated with shorter survival especially 
in patients with lymph node involvement.  
Hashimoto et al. [127] 
30 NSCLC patients 
Stage I to IV 
CellSearch 73% in PV blood 
before surgery 
CTC count in PV blood significantly 
increased after surgery, which predicted 
lymphatic tumor invasion.  
Funaki et al. [128] 
130 NSCLC patients 
Stage I to IV 
RosetteSep kit 74% in PV blood after 
tumor resection  
circulating tumor 
microemboli (CTM) 
in 33% 
The presence of CTM in PV blood 
predicted worse PFS.  
Chudasama et al. [129] 
20 NSCLC patients 
Stage III-IV 
 
ScreenCell  25% at baseline, 75% 
after endobronchial 
cryotherapy (EC) 
CTC count increased after EC. 
Carlsson et al. [122] 
104 NSCLC patients 
Stage I to IV 
25 patients with benign 
diseases 
HD-CTC assay 50% positive to CTM CTM along with clinical and imaging data 
can serve as predictor of malignant versus 
benign diseases. 
Pirozzi et al. [135] 
45 NSCLC patients 
Stage I to III 
Ficoll-Hypaque 
Centrifugation 
24% in PV blood No association found between presence of 
CTCs and prognosis.  
 
Nel et al. [131] 
43 NSCLC patients  
Stage IIB-IV 
Ficoll-Paque 
CD45 magnetic 
depletion 
100% Presence of mesenchymal markers CD133 
and N-cadherin in CTCs predicated shorter 
PFS. 
Hou et al. [133] 
97 SCLC patients  
CellSearch 
and ISET 
CTCs in 85% 
CTM in 32% 
More than 50 CTCs/7.5ml blood 
predicated shorter OS.  
. 
Huang et al. [134] 
26 SCLC patients 
 
CellSearch Not reported 
Median CTC count at 
baseline is 75 (0-
3430) 
CTC count decreased after chemotherapy.  
CTC count at baseline and change of CTC 
numbers after treatment not associated 
with survival.  
Table 3. CTCs as prognostic markers in lung cancer 
Taken together, several studies have demonstrated the prognostic utility of CTCs 
in lung cancer. CTC count and change of CTC number after surgery, radiation and 
chemotherapy may serve as predictors of recurrence.  At the current time, however, CTCs 
are not routinely used as prognostic or predictive markers in clinic.  There are several 
reasons for this. Most of the previous studies used CellSearch or traditional approaches 
without pre-enrichment that limited sensitivity of the tests for detecting CTCs. Many of 
the studies had small sample sizes (<100) limiting statistical significance, which resulted 
in contradictory or inconclusive findings.  Given newer and more sensitive technologies 
that allow isolation and accurate characterization of CTCs, large numbers of patients 
within specific stages of lung cancer need to be enrolled. Stringent biomarker studies 
using training and test sets will allow independent validation and reproducibility.  
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1.3.4 Applications of CTCs in the era of targeted therapies in lung cancer 
The past 2 decades have seen a large discovery effort such that lung cancer is not 
considered one homogenous cancer. Over 64% of all lung cancers have an underlying 
driver mutation that is responsible for proliferation of the cancer and many of these 
mutations are mutually exclusive [136]. Nearly 30% cases of these driver-mutant lung 
cancers have an approved therapy (targeted therapy). The most common ones are 
adenocarcinomas (AC) that are associated with mutations in the EGFR gene or 
rearrangements in the ALK and ROS-1 gene [137]. Additional genomic aberrations 
include those in  BRAF, AKT1, ERRB2, PIK3CA, and fusions in RET [138]. Detection of 
mutations by biopsy may not fully reflect intra-tumoral heterogeneity [139]. In this 
regard, sampling CTCs as “liquid biopsy” may complement solid biopsy to inform 
effective targeted therapies. Liquid biopsy is also noninvasive allowing dynamic 
monitoring of disease progression [64].  
One of the earliest investigations was identifying EGFR mutations in CTCs from 
metastatic NSCLC known to harbor these mutations. In 11 out of 12 patients, expected 
mutations were validated including the appearance of the resistance mutation T790M. In 
this study, CTC numbers paralleled radiographic response and offered first insights into 
genomic profiling of CTCs as a way to monitor genotypic changes during therapy [27]. 
Two recent studies examined EGFR mutation in advanced NSCLC patients. Marchetti et 
al. demonstrated that EGFR mutation was detected in CTCs of 84% of the patients 
carrying EGFR mutant primary tumors [140]. In 94% of the cases, mutations found in 
CTCs matched the mutations in tumor tissues. The unmatched mutations in CTCs and 
primary tumors were likely due to tumor heterogeneity between primary lesions and 
metastatic sites. Breitenbuecher et al. utilized a RT-PCR assay to detect in-frame 
deletions in the EGFR exon 19 [141]. All 8 EGFR-mutant patients demonstrated identical 
mutations in the CTCs. EGFR mutations were also detected from circulating DNA of 
advanced lung adenocarcinoma patients with 73% sensitivity [142]. Both CTCs and 
cfDNA can be used in future research to determine the “best in class” EGFR tyrosine 
kinase inhibitors (TKI) for individual patients.  
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Other studies focused on investigating ALK rearrangement in CTCs [89, 143]. By 
performing filter-adapted fluorescent in situ hybridization (FA-FISH), researchers 
identified unique ALK rearranged pattern in CTCs with mesenchymal phenotypes. This 
unique population of CTCs may be highly invasive, behaving as metastasis initiating 
cells [144]. Adapting the similar approach, ROS1 rearrangement was investigated in 
NSCLC CTCs and compared to tumor biopsy specimens [90]. Among 4 patients tested, 
CTCs harbored similar split patterns as tumors but exhibited an increase in ROS1 copy 
number. The number of ROS1 rearranged CTCs increased in one patient who didn’t 
respond to crizotinib treatment. In another study, whole-genome amplification of single 
CTCs from lung cancer patients was performed followed by analyzing copy number 
variation (CNV) in addition to somatic mutations [88]. It was demonstrated that CTCs 
obtained from the same patient exhibited similar CNV pattern but was distinguishable 
from CTCs obtained from a different histology of lung cancer. These studies suggest that 
profiling CTC genome predicts cancer progression as well as emergence of secondary 
resistant mechanisms, which can be further targeted by second-line therapies.  
1.3.5 CTCs as biomarkers for early diagnosis of lung cancer 
Sensitive detection of CTCs provides opportunities for early diagnosis of lung 
cancer. CTCs can be shed by primary tumor even at early stages of tumor development 
[145, 146]. It was demonstrated that the presence of CTCs in 5 out of 168 chronic 
obstructive pulmonary disease patients predicted occurrence of lung nodules 1 to 4 years 
after initial detection of CTCs [147]. In one study, CTCs were isolated from 84% of lung 
cancer patients of various stages including early stage of lung cancer (57.1%) [148]. 
CTCs were identified with CD45-FISH method, which was reported to increase detection 
sensitivity by including cells deficient in epithelial markers like CK.  Two studies utilized 
tumor-specific ligand folate and an oligonucleotide followed by qPCR and 
immunofluorescence staining to identify NSCLC CTCs [149, 150]. CTCs were observed 
in more than 70% of all stages with 67.2% in stage I cancer. It was further demonstrated 
that CTCs can be more sensitive for early diagnosis of lung cancer than blood serum 
markers such as cyfra21-1 or CEA.  More recently, one study evaluated CTCs from 
potential lung cancer patients to predict malignancy of the lung lesions as a way to 
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circumvent sampling bias by solid biopsy [151]. CTCs shared similar morphological 
features and histology (72%) with biopsy specimens. In stage I patients (42%), the 
numbers of CTCs correlated with tumor size (P=0.001). Our group also demonstrated 
that CTCs were detectable in early stages of lung cancer (68%) [77].  Early diagnosis of 
cancer aided by liquid biopsy is challenging due to low abundance of CTCs. Therefore, it 
is necessary to develop more sensitive and specific technologies such that more inclusive 
characterization methodologies will aid in early detection of lung cancer. 
1.4 CTCs in esophageal cancer 
Esophageal cancer is one of the least studied and most aggressive cancers 
worldwide. The five-year survival rate is 20% [152]. In the year 2015, 16,980 new cases 
and 15,590 deaths are estimated in the US [153]. Esophageal cancer has a tendency to 
spread early in the tumor development [154]. More than 50% of the patients have either 
unresectable tumor or visible metastases at the time of diagnosis. Alcohol and smoking 
are the risk factors for esophageal cancer [155]. Consuming extremely hot beverages 
frequently also increases the risk [156].  In addition, the gastroesophageal reflux disease 
is associated with an increased risk [157]. Clinical diagnostic methods of esophageal 
cancer include esophagogram and endoscopy. A computed tomographic (CT) scan, 
positron-emission tomography (PET) scan or endoscopic ultrasonography is used to 
detect invasion to the lymph nodes and other metastatic diseases [158]. Serum marker 
tests such as carcinoembryonic antigen and cancer antigen (CA) are normally conducted 
to accompany with the CT examination. However, the blood marker tests are limited with 
low sensitivity and specificity [159]. There is an unmet need to incorporate additional 
biomarkers for accurate preoperative/pretreatment staging and stratification of patients as 
well as post-therapy monitoring.  
Several studies have investigated the role CTCs plays in prognosis and predicting 
treatment response in esophageal cancer. Sclafani et al. conducted a small pilot study of 
18 patients with advanced esophageal or gastric adenocarcinoma and evaluated CTC 
counts in the patients during the course of chemotherapy using the CellSearch technology 
[160]. More than 2 CTCs were detected in 44% of patients at baseline. Recently, 
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Matsushita et al. reported a larger cohort study [161]. Ninety patients with esophageal 
squamous cell carcinoma (ECSS) were enrolled. Using CellSearch technology, CTCs 
were identified in 27.8% of patients at baseline. CTCs were evaluated in the follow-up 
samples from 71 patients during treatment. CTC positivity was shown to correlate with 
worse OS (P=0.002). A reduction in CTC number after treatment predicted partial 
response and positive therapeutic efficacy (P=0.034). Consoli et al. observed the presence 
of CTCs after one esophageal cancer patient developed cardiac metastasis [162]. Reeh et 
al. examined the prognostic significance of CTCs in 100 esophageal cancer patients [163]. 
CTC were identified in 18% patients and CTC positivity predicted worse OS (P<0.001) 
and tumor recurrence (P<0.001). They found that the presence of CTCs was correlated 
with metastatic stage (P=0.013).  
To account for heterogeneous CTC populations by including cells that are 
negative for EpCAM, Li et al. recently detected CTCs using both CellSearch and ISET 
technologies [164]. Sixty-one patients with esophageal squamous cell carcinoma were 
recruited and their CTC numbers were analyzed by the two methods. CTCs were detected 
in 32.8% patients by ISET and 1.6% by CellSearch. CTM were observed in 4.9% patients 
by ISET and undetectable by CellSearch. This suggests CTC counts may be 
underestimated using CellSearch. Bobek et al. used another size-based technology 
(MetaCell) to detect CTCs in 43 esophageal cancer patients [165]. 62.8% of patients were 
positive for CTCs. The CTCs were cultured directly on the filters allowing further 
immunohistochemical analysis.   
These studies highlight the potential utility of CTCs in monitoring tumor 
progression and treatment response. This is likely to help with pretreatment evaluation of 
patients, follow-up monitoring and predicting tumor recurrence. However, there is a 
discrepancy of CTC detection rate in ESCC patients between different studies, which is 
likely due to small cohort of patients, different tumor stages, and ethnicities. Most studies 
evaluating prognostic value of esophageal CTCs used the FDA approved CellSearch 
technology which is limited with detection sensitivity and available downstream assays 
[166]. Further studies need to incorporate more sensitive detection methods and 
esophageal cancer specific markers for CTC identification or characterization. 
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Chapter 2 
CTC isolation by a transparent polymer based 
microfluidic CTC-capture device 
 
 
 
2.1 Abstract 
 
Microfluidic based isolation technologies offer high sensitivity and specificity due to the 
microscale manipulation of cells. CTCs can be positively selected by antibodies targeting 
cell surface antigens. One of the most widely used antibodies is the antibody against the 
epithelial cell adhesion molecule (EpCAM). We developed a microfluidic CTC-capture 
device utilizing the immunoaffinity principle. The device is made of 
polydimethylsiloxane (PDMS) and exhibits high optical property. The CTC-capture 
device consists of arrays of microposts, which enhance the interaction between fluid and 
surface, thereby increasing the CTC capture efficiency. We evaluated the device with 
H1650 and A549 cells (lung cancer cell lines). The capture yields are 100% and 50% 
respectively due to different level of EpCAM expression. Furthermore, the CTC-capture 
device successfully detected CTCs in the peripheral blood of early stage lung (68%) and 
esophageal (86%) cancer patients. We show that the CTC-capture device provides an 
effective method to identify and characterize CTCs in early stage cancer patients and 
contributes to early cancer detection. 
29 
	
2.2 Introduction 
The presence of CTCs in the blood stream is prognostic for cancer patients[167]. 
Detecting CTCs in early stage cancer patients aids in cancer diagnosis and staging[60]. In 
the past decade, microfluidic technologies have been developed to enhance the isolation 
efficiency and specificity of rare CTCs[168]. Microfluidic devices apply low shear stress 
on cells with minimal damage to them. One of the major CTC detection methods is 
targeting antigens uniquely expressed by cancer cells but not by blood cells. Early in 
2007, Nagrath et al. reported that the CTC-chip coated with EpCAM identified CTCs in 
metastatic breast, lung and prostate cancer patients [26]. This silicon based microfluidic 
device had limited optical property, which might hinder the subsequent characterization 
of CTCs. Later, an alternative strategy called the Herringbone (HB)-chip was developed 
to capture CTCs from patients with metastatic prostate cancer [32]. Both the CTC-chip 
and HB-chip utilized complex geometries in the microchannel to increase the contact 
between cells and antibody-coated surfaces. In the present study, we introduce a CTC-
capture device using polydimethylsiloxane (PDMS), an organic polymer, and a glass 
slide. The CTC-capture device is transparent and of low cost. In addition, the 
functionalized area of the device for CTC capturing is increased compared to the CTC-
chip because the glass slide is also coated with antibodies. Hence, the CTC capture 
efficiency is enhanced.  
 
2.3 Methods 
 
2.3.1 Design and computational fluid dynamic simulation of the CTC-capture device 
The CTC-capture device was based on the micropost architecture originally 
published by Nagrath et al. in 2007 [26]. The dimension of the device was determined 
such that it can fit onto a 1 inch by 3 inch glass slide. Specifically, the channel contained 
one inlet and one outlet. In the middle of the channel, there were arrays of cylindrical 
microposts. Each post was 100µm in diameter and the array was shifted every 10 
columns. The depth of the channel is 100µm. This shift helped to increase fluid-surface 
interactions such that cancer cells could encounter the surfaces more efficiently.  
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A Comsol simulation using finite element fluidic solver was conducted to 
demonstrate the efficiency of the post arrangement. The flow rate at inlet was 1mL/hr. 
Due to the memory limitation of the computer, a section of the post structure was drawn 
in the software only to demonstrate the fluid interactions with the posts. We evaluated the 
fluid flow using both the “Laminar fluid” module and the “Particle tracing” module.  
 
2.3.2 Fabrication and functionalization of the CTC-capture device 
The mold of the CTC-capture device was fabricated in the Lurie Nanofabrication 
Facility (LNF) at the University of Michigan. Specifically, a small amount of negative 
photoresist SU-8 100 (MicroChem) was deposited on one 4 inch silicon wafer 
(UniversityWafer). The wafer was spun initially at 500rpm for 10 seconds immediately 
followed by spinning at 2280-2300rpm for 60 seconds. Then the wafer was baked on a 
hot plate at 65 degree C for 10 minutes followed by baking at 95 degree C for 60 minutes. 
Then the SU-8 coated wafer was taken to expose for 18 seconds under the UV light in a 
MA/BA-6 Mask/Bond Aligner in the clean room of LNF. The exposed wafer was then 
developed in the Wet Chemistry lab at the LNF. Before developing, the wafer was baked 
at 65 degree C for 5 minutes followed by baking at 95 degree C for 10 minutes. The 
wafer was then placed in the SU-8 developer for 8 min for the SU-8 to develop. Since 
SU-8 is a negative photoresist, the UV exposed areas remain after developing. Therefore 
the micropost areas in the film mask were black and got washed away through 
development. The developed SU-8 mold was further baked at 150 degree C to seal the 
micro-cracks near the edges of the structures. Finally, PDMS polymer mixed with its 
curing agent was poured on the SU-8 mold. After degasing in a dessicator for 2-3 hours, 
the mold with PDMS was transferred to a 75 degree oven to cure PDMS overnight. The 
next day, the cured PDMS was cut and peeled from the mold. The PDMS containing post 
structures was then treated with plasma and bonded to one plasma activated glass slide. 
The bonded device was then placed on a hot plate at 85 degree C to reinforce the bonding.  
To functionalize a device, surface chemistry treatment was conducted after 
bonding the PDMS to a glass slide. Specifically, immediately after hot plate treatment of 
the bonded device, 4% mercaptopropyltrimethoxysilane (Gelest) in 200 proof ethanol 
was injected into the device three times from inlet and three times from outlet followed 
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by incubation for 1 hour. Then, silane was washed away with pure ethanol. 280ng/µL N-
gamma-maleimidobutyryl-oxysuccinimide ester (GMBS) (Thermo Scientific) was then 
injected into the device three times from inlet and three times from outlet followed by 
incubation for 30 minutes. Then GMBS was washed away with ethanol. 100µg/ml of 
NeutrAvidin (Invitrogen) was then injected to the device. The device can be used after 1 
hour of incubation in NeutrAvidin or it can be stored at 4 degree C for up to months 
before the solution was dried up. Figure 5 demonstrates the fabrication and surface 
treatment process. Biotinylated antibody in 1% bovine serum albumin (BSA) (Sigma-
Aldrich) solution was injected into the device. It was achieved by injecting from the inlet 
and incubating for 30 minutes followed by injecting from the outlet and incubating for 
another 30 minutes. Finally, 1mL of 3% BSA solution was flowed through the device at 
3mL/hr. The device was ready to flow with blood for CTC capturing.  
 
 
Figure 5. Process of device fabrication and functionalization. A SU-8 mold is 
fabricated using soft-lithography method. After the PDMS is bonded to a glass slide, 
silane is first reacted with plasma activated glass and PDMS, then GMBS is reacted with 
silane and serves as a linker molecule. NeutrAvidin is then applied to link to GMBS and 
finally the biotinylated antibody is attached. 
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2.3.3 Preparation of spiked cells 
To characterize the capture efficiency of the device, known numbers of cancer 
cells were spiked into phosphate buffered saline (PBS) or whole blood drawn from 
healthy donors. The spiked cancer cells were prepared as follows. Cultured cancer cells 
were trypsinized and pre-labelled with CellTracker Green CMFDA Dye (Invitrogen). 
Specifically, cell pellets were washed one time in PBS followed by re-suspending in 5mL 
of serum free medium. Each vial of the CellTracker dye was dissolved in 10µL of 
dimethyl sulfoxide (DMSO). 5µL of the CellTracker dye solution in DMSO was then 
added to the 5mL of serum free medium containing cancer cells. The cells were then 
incubated at 37 degree C for 30 minutes. After that, the cells were washed twice in 5mL 
of PBS and re-suspended in complete medium followed by incubating at 37 degree C for 
another 30 minutes. Then the cells were washed two more times in PBS. Finally 1000 or 
100 cells were counted either using a hemocytometer or by spot counting under a 
fluorescence microscope. The cells were spiked into 1mL whole blood or PBS to 
complete the preparation procedure.  
2.3.4 Cell capture experiments 
Typically, 1mL of the sample containing spiked cancer cells was flowed through 
the EpCAM coated device at 1mL/hr for CTC capturing. The device was then washed 
with PBS at 10mL/hr for 10mL to get rid of non-specifically bound cells. 1mL of 4% 
paraformaldehyde solution was then flowed through the device at 3mL/hr to fix the 
captured cells. After the labelled cancer cells were captured and fixed. 1mL of 0.2% 
triton solution in PBS was flowed through the device followed by flowing 1mL of DAPI 
solution into the device to stain nucleus of the cells. After that, the device was ready to be 
imaged and scanned under a fluorescence microscope with an automated moving stage. 
Normally there would be around 800 images acquired under a 10X objective. Each image 
was reviewed and captured cancer cells were enumerated. The capture efficiency was 
calculated by dividing this number by the initial spiked cell number. Each experiment 
was performed in triplicate.   
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2.3.5 Immunofluorescence staining of captured cancer cells on chip 
To test the on-chip immunofluorescence (IF) staining protocol, unlabeled cancer 
cells were counted and spiked into whole blood. Specifically, after the captured cells 
were fixed and permeabilized. 1mL of 2% normal goat serum and 3% BSA solution was 
flowed through the device to block the cells for 1 hour. Then 1mL of 5 µg/mL of 
cytokeratin 7/8 (CK 7/8) (CAM5.2, BD) and CD45 (HI30, BD) was flowed through the 
device at 3mL/hr and incubated for 1 hour. After that, primary antibodies were washed by 
PBS at 10mL/hr for 3 mL followed by applying secondary antibodies, goat anti-mouse 
IgG2a-AF546 and goat anti-mouse IgG1- AF488, at 1:200 dilution for 1 mL in 1% BSA. 
The secondary antibodies were incubated in device for 1 hour followed by washing with 
3mL PBS. Finally, 1mL of DAPI solution was flowed through the device and incubated 
for 30 minutes. The device was washed again with 3mL of PBS and could be scanned 
with microscope or stored at 4 degree C.  
 
2.3.6 Acquisition of blood samples from early stage cancer patients 
The CTC-capture device was tested with patient samples from early stage lung 
and esophageal cancer patients. Peripheral blood samples were drawn from cancer 
patients prior surgery at University of Michigan Hospital under an IRB-approved 
protocol. All patients involved in this study had surgically resectable early stage cancers. 
Upon CTC isolation, the devices were IF stained with antibodies for enumerating CTCs. 
The staining method is the same as the one described in the cell line experiments. 
 
2.4 Results 
 
2.4.1 The CTC-capture device 
The design and appearance of the CTC-capture device is shown in Figure 6. 
Figure 6a is an AutoCAD drawing demonstrating the arrangement of the microposts. The 
surface area of the device is greatly enhanced with the post structures. Figure 6b is a 
SEM image of the microposts. In addition, Figure 6c is an actual CTC-capture device 
with blood running through the device. The Comsol simulation shown in Figure 7 
demonstrates the fluid interaction with the microposts. Because of the column-shift, 
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streamlines are shifted periodically to enhance the interaction between fluid and 
microposts. The interaction enables CTCs to come closer to the surface and get 
specifically captured by the antibodies coated on the surface. This is simulated by 
“Particle Tracing” module in Comsol, which demonstrates how the particles are stuck by 
the post structures in the channel.  
 
 
Figure 6. The CTC-capture device. a. The post arrangement is drawn with AutoCAD. b. 
Post structures are imaged with the Scanning Electron Microscope. c. An actual device 
made of PDMS is running with whole blood. 
 
 
 
 
Figure 7. Comsol simulation of the micropost structures. Fluid simulation is 
performed to show the velocity field and particle tracing of the post arrangement inside 
the microfluidic device. 
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2.4.2. Characterization of the CTC capture efficiency using cancer cell lines 
Figure 8 demonstrates the capture yield of two different lung cancer cell lines. 
H1650 cells express EpCAM abundantly (106 markers/cell) while A549 only have 
moderate (104 markers/cell) EpCAM expression [169]. The capture efficiency of H1650 
was 87% at a 10 cells/mL concentration and almost 100% at concentrations of 100 and 
1,000 cells/mL of whole blood. The capture efficiency was lower in PBS because the 
cell-surface interaction was enhanced by blood cells. The capture efficiency of A549 was 
lower than H1650, around 60% with 1000 cells and 50% with 100 or 10 cells. This was 
due to lower EpCAM expression. The immunofluorescence images demonstrate that 
cancer cells are specifically captured by the micropost structures. The device exhibits 
good optical properties for acquiring images of high quality, which is demonstrated by 
the confocal microscopy images shown in Figure 8c. To distinguish cancer cells from 
blood cells for CTC enumeration, the captured H1650 lung cancer cells were 
immunofluorescence (IF) stained for CK 7/8(green), white blood cells were stained for 
CD45 (red) and nuclei were counterstained for DAPI. These results demonstrate that the 
CTC-capture device can reliably isolate CTCs from whole blood with high sensitivity and 
efficiency even for low numbers of cells. 
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Figure 8. Characterization of the CTC capture device with cancer cell lines. a. 
Capture yield of H1650 lung cancer cell lines spiked in buffer or whole blood; b. Capture 
yield of A549 lung cancer cell lines spiked in whole blood; c. Immunofluorescence 
staining of the captured H1650 lung cancer cells in the device, CK(green), CD45(red).   
 
 
2.4.3 Isolation of CTCs from patients with early stage lung and esophageal cancers  
After the CTC-captured device was tested with cancer cell lines and demonstrated 
high capture efficiency, we evaluated the device with actual patient samples, which were 
peripheral blood samples from early stage lung and esophageal cancer patients. We 
observed the CTC numbers ranged from 1-11/mL (mean=4, median=3, SD=3) in lung 
cancer patients and 1-21/mL (mean=8, median=6, SD=6) in esophageal cancer patients. 
CTCs were identified in 68% of lung cancer patients (total=19, positive=13) and 86% of 
esophageal cancer patients (total=14, positive=12), whereas none of the healthy 
volunteers (n=7) showed CK positive cells greater than 2/mL (Figure 9). Figure 10 
demonstrates the stained CTCs recovered from lung and esophageal cancer patients. The 
patient CTCs were identified as CK (red) positive and CD45 (green) negative cells.  
 
 
 
Figure 9. Number of CTCs captured from 1mL peripheral blood of healthy controls, 
NSCLC cancer patients and esophageal cancer patients. Healthy controls (n=7), 
mean=0.6; lung cancer patients (n=19), mean=4; esophageal cancer patients (n=14), 
mean=8. CTC positive samples are determined as >2 CTCs/mL. 
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Figure 10. A gallery of captured CTCs from lung and esophageal cancer patients. 
CTCs are stained with CK(red) and CD45 (green). CTCs are identified as CK positive 
and CD45 negative cells. White blood cells are CK negative and CD45 positive. 
 
 
2.5 Discussion 
We developed a CTC-capture device to specifically isolate CTCs using 
immunoaffinitiy-based approach. The micropost structures enhance the fluid and surface 
interactions. Based on the spiked cell results, we demonstrate the CTC-capture device 
isolates CTCs with high yields. The capture efficiency of H1650 was nearly 100%, and 
A549 was 50% due to the low level of EpCAM expression on the cells. To circumvent 
this problem, other capturing antibodies such as those against epidermal growth factor 
receptors (EGFR) and CD133, a stem cell marker, can be incorporated in the future to 
enhance the capture efficiency. The ability of isolate CTCs with high specificity and 
efficiency depends on the choice of detection technologies. Microfluidic devices have 
emerged to provide versatile platforms to isolate CTCs with high sensitivity and purity. 
Building upon the previous published CTC-chip technology, the present CTC-capture 
device offers advantages such as enhanced optical property, biocompatibility and low 
cost. These improvements will facilitate its translation from bench to bedside in the future.  
Shedding CTCs by primary tumors can be an early event in tumor development 
[20]. Previous studies have demonstrated that CTCs can be detected in patients with early 
stage cancers [149, 150]. In this study, we also observed CTCs were identified in patients 
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having early stage lung and esophageal cancers. The isolated CTCs were either single 
cells or cell clusters. Although our study is limited to a small number of patient samples 
and the CTC numbers vary substantially between samples, the present study indicates the 
possibility of detecting CTCs in large cohorts and monitoring the change of CTC number 
during treatment. Isolating CTCs can have vast implications in cancer diagnosis, 
prognosis and assist with early lung and esophageal cancer detection.  
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Chapter 3 
Three-dimensional microfluidic co-culture model for 
the expansion of CTCs 
 
 
3.1 Abstract 
 
Microfluidic devices have been demonstrated as in vitro systems for cell culture. The 
microsystems handle small volumes of materials and allow dynamic control of the 
cellular environment. Here, we developed a multi-inlet microfluidic device that could 
pattern cancer cells and stromal cells using laminar flow. The patterned cells were 
cultured in a mix of collagen and Matrigel representing a tumor microenvironment, 
which allows the study of cell-cell communications. The microfluidic co-culture 
methodology was further applied to culture CTCs on chip. The motivation of culturing 
CTCs comes from the need to increase CTC yield for downstream assays, especially in 
the early stage cancer patients. Using the three dimensional co-culture model, a tumor 
microenvironment was simulated to support tumor development. CTCs were isolated and 
expanded from 14 of 19 lung cancer patients and 10 of 14 esophageal cancer patients. All 
of the cancer patients had surgical resectable tumors. Expanded lung CTCs carried 
mutations of the TP53 gene identical to those observed in the matched primary tumors. 
Next-generation sequencing further revealed additional matched mutations between 
primary lung tumors and CTCs of cancer-related genes. This strategy sets the stage to 
further characterize the biology of CTCs derived from patients with lung and esophageal 
cancers, thereby leading to a better understanding of these putative drivers of metastasis.  
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3.2 Introduction 
 
3.2.1 Cell patterning and culturing by microfluidic platforms 
Polydimethylsiloxane (PDMS) has become a standard material for microfluidic 
research community due to its ease of fabrication, versatility for making various 
geometries, and compatibility with imaging. PDMS-based microfluidic platforms have 
also been utilized to culture mammalian cells in vitro. PDMS permits gas exchange, 
which is essential for cells to grow. Although there are some concerns about PDMS 
absorbs hydrophobic molecules in culture such as estrogen, it has been widely used as the 
material to construct microfluidic devices for cell culture [170] and the adverse effect on 
cells is minor. The motivation of culturing cells in a microfluidic device is the ability to 
control the cellular microenvironment through spatial and temporal gradients [171]. In 
addition, cells can be patterned to study the dynamic interplay between different cell 
types. Compared to conventional cell culture techniques, microfluidics provides a better 
approximation to cellular environment by precisely controlling concentration gradients, 
extracellular matrix components and cell-cell interactions [172].  
In the tumor microenvironment, there are the surrounding non-malignant cells and 
extracellular matrix (ECM). The tumor microenvironment plays a dynamic role during 
tumor progression, which evolves from tumor inhibiting to promoting. Cancer cells and 
surrounding stromal cells communicate through paracrine signaling pathways such as the 
transforming growth factor beta (TGFβ), epidermal growth factor (EGF), colony 
stimulating factor 1 (CSF1), C-X-C chemokine receptor 4 (CXCR4) and stromal cell-
derived factor 1 (SDF1 or CXCL12) [173]. These pathways are important for cancer 
proliferation and invasion. Understanding the tumor microenvironment will have vast 
implications in drug development and screening.  
In this present study, we created a multi-inlet microfluidic device to pattern 
cancer cells and fibroblasts, which are the major component of cancer stroma [174]. This 
allows us to visualize the interaction between the two cell types. This proof-of-concept 
study demonstrates the feasibility of using microfluidic devices to culture cells and study 
tumor microenvironment in vitro. 
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3.2.2 Ex vivo expansion of CTCs  
Studies indicate that CTCs are useful prognostic and predictive markers of 
recurrence and survival in patients with solid cancers, including lung and esophageal 
cancer [27, 70, 84, 133, 175-178]. CTCs may serve as reliable biomarkers for detecting 
cancer recurrence earlier than other commonly used approaches, such as radiographic 
imaging. By the time metastasis is clinically or radiographically apparent, the tumor 
burden is too high for available therapies to cure the cancer. Studies in advanced lung and 
esophageal cancer and other malignancies show that elevated numbers of CTCs are 
associated with reduced progression free and overall survival [179]. However, these 
studies also emphasize that not all CTCs lead to metastasis. It is crucial to identify the 
CTCs that are capable of metastasis from the ones that are mere “passengers” in order to 
specifically target the former.  Importantly, identifying specific genetic signatures in 
CTCs, the earliest cells with metastasis-initiating capability, will provide new therapeutic 
targets. However, to achieve this, one needs to characterize CTCs from early cancers at a 
molecular and genomic level.  
In this study, an immunoaffinity-based CTC-capture device was utilized and 
applied it to early stage lung and esophageal cancer. To overcome rarity of CTCs that 
limits characterization for clinical utility, these CTCs were isolated and further cultured 
on chip. To date, culturing of CTCs has only been demonstrated by a few groups, albeit 
in CTCs recovered from animal models or in a few patients with advanced cancers, 
where the likelihood of finding higher numbers of CTCs was greater [37, 97, 180]. 
Different from these previous approaches, and as opposed to culturing CTCs off devices, 
here the captured CTCs were cultured directly on microfluidic chips. It is only after 
CTCs are expanded on-chip for a long period of time that they are released for subculture 
or downstream analysis. To facilitate CTC expansion, tumor associated fibroblasts (CAFs) 
along with extracellular matrix (ECM) proteins are introduced to construct a tumor 
microenvironment conducive for CTC growth (Figure 11). We demonstrate that rare 
CTCs from early stage cancers can be expanded for functional studies such as invasion 
and tumor spheroid forming assays, as well as sequencing of cancer related genes 
enabling comparison between CTCs and primary tumor cells.  
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Figure 11. Overall strategy of the 3D microfluidic co-culture model for CTC 
culturing. The first step is to capture CTCs by flowing patient blood sample through a 
CTC-capture chip. The second step is to introduce fibroblasts and extracellular matrix 
(ECM) to the same chip to establish a co-culture environment for ex-vivo expansion of 
CTCs. The third step is to release and recover CTCs from device and the fourth step is 
downstream characterizations. 
 
3.3 Methods 
 
3.3.1 Design and fabrication of the multi-inlet microfluidic cell culture device 
The microfluidic device consisted of three inlets, which were merged to form a 
middle channel for patterning different types of cells side by side. At the end of the 
middle channel, there was one outlet. The dimension of the device was determined such 
that the whole device can be fitted onto a 22mmx22mm cover glass. Each device bonded 
with a cover glass can be put into one well of a 6-well plate. The inlets were punched 
with a biopsy punch of 3.5mm in diameter. The big ports served as reservoirs of cell 
suspension and cell culture medium. The outlet was initially punched with a 0.75mm 
diameter punch to apply vacuum for establishing the laminar flow. After the cells were 
patterned and settled down in the device, the outlet was again punched with the 3.5mm 
punch and served as a reservoir for medium exchange. One completed device needed to 
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be autoclaved before adding cell suspension. This ensured the culture was free of 
contamination.  
3.3.2 Fluorescein bead testing 
To test the patterning efficiency of this device, solution containing fluorescein 
beads was applied in the middle inlet while the other two inlets on the sides contained 
plain PEG-800 solution. Specifically, 50µL of 100mg/mL PEG-800 solution in PBS was 
added to the left and right ports. 50µL of 200mg/mL PEG-800 solution mixed with 0.45 
µm fluorescein bead solution (1:1 volume ratio) was added in the middle port. The reason 
to use PEG-800 solution was that it shared the same viscosity as the cell suspension in 
Matrigel.  
 
3.3.3 Experimental methods for cell patterning and culturing in the multi-inlet 
microfluidic device 
The human mammary fibroblasts (HMFs) were added to the left and right inlets 
while the MCF7 cells were loaded in the middle inlet. Both types of cells were suspended 
in Matrigel (50% by volume) (BD Bioscience) on ice and they were patterned in the 
middle channel after applying vacuum by a syringe pump. After that, the device was 
placed in one 6-well plate and was incubated at 37 degree C for 30 minutes to let the 
Matrigel set. Then medium was added to the inlet and outlet ports to replenish nutrients 
and exchange waste. Medium was changed every other day. The culture was maintained 
till cells grew to confluency. IF staining was performed to visualize cancer cells and 
fibroblasts on chip. 
 
3.3.4 Co-culture techniques for CTC expansion 
GFP-tagged A549 (Cell Biolab) and H1650 cells were spiked into whole blood 
and flowed through the CTC-capture device. One hundred H1650-GFP cells were 
captured and cultured in the device. Different cell culture environments were tested and 
compared: 3D co-culturing: 105 cancer associated fibroblasts were mixed with 0.97 
mg/mL collagen I (BD Bioscience) and 50% Matrigel (BD Bioscience) [181]. The final 
concentration of collagen I was 0.77 mg/ml. 3D mono-culturing: only the collagen I and 
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Matrigel mixture was added. 2D co-culturing: only fibroblasts were added. 2D mono-
culturing: neither fibroblasts nor gel was added. These experiments were conducted in 
triplicate for each culturing condition. Collagen, Matrigel and fibroblasts were flowed 
into the device at a flow rate of 1 mL/hr for a total volume of 200 µl. A scanning electron 
microscopy image was taken to illustrate the 3D co-culture environment on chip. A 
proliferation EdU assay (Invitrogen) was carried out to evaluate the proliferation 
potential of the cultured cancer cells on day 7 in device.  
3.3.5 GFP lentivirus transfection of CAFs 
CAFs need to be pre-labelled with GFP vectors so that they can be distinguished 
from the cancer cells after expansion. To label the CAFs, 2X GFP lentivirus was added to 
each well of one 6-well plate containing around 1000 CAFs and incubated overnight. The 
next day, viral medium was exchanged with fresh complete medium. The transfected 
CAFs were cultured till confluency. Finally, the labelled CAFs can be sorted by flow 
cytometry to select the most expressing populations and to be cultured further for the chip 
experiments.  
3.3.6 CTC expansion with early stage lung and esophageal patient samples 
Peripheral blood samples were drawn from early lung and esophageal cancer 
patients at University of Michigan Hospital under an IRB-approved protocol. Blood 
specimens from healthy donors were collected according to a separate IRB. The blood 
sample from each patient was divided equally into 1-1.5mL aliquots and run through 3-4 
devices. One device was IF stained for counting CTC numbers on day 0. The remaining 
devices were used for CTC culturing. To culture CTCs, a mixture of cancer associated 
fibroblasts-GFP, collagen I and Matrigel was added into the devices. Each device was 
then incubated in a 37 degree, 7.5% CO2 incubator for 30 minutes to facilitate gel 
formation. After that, medium was added to the device for culturing up to 7 days. 
Medium was RPMI complete medium (10% FBS and 1% Penicillin/Streptomycin).  
3.3.7 CTC release and recovery 
After 7 days of on-chip culture, cells were released from the device by first 
incubating with collagenase for 4 hrs and then 0.25% trypsin/EDTA at 37 degree in a 7.5% 
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CO2 incubator for 30 minutes. Then cells were flushed outside the device with media at 
10 mL/hr flow rate for 3 mL totally. Around 90% of the cells were released from the 
device. The recovered cells were re-seeded in a well plate and cultured for an additional 
7-14 days.  
3.3.8 Immunofluorescence cell staining 
Cells in well plates were fixed with 4% PFA and permeabilized with 0.1% Triton 
in PBS. The cells were then blocked with 5% normal goat serum and 1% BSA in PBT 
solution. Cells were later immunostained with CK7/8 or TTF-1 (Santa Cruz 
Biotechnology) or Ki67 (Invitrogen) as well as the corresponding secondary antibodies.  
The CK7/8 positive cells were enumerated. After FACS sorting, CTCs were stained with 
EGFR (Cell Signaling) and pan-CK (Biolegend). 
3.3.9 Spheroid formation assay 
CTCs together with fibroblasts cultured in well-plates were trypsinized, counted 
and re-suspended in a mix of collagen and Matrigel at a concentration of 106 cells/mL. 
Two hundred µL of gel plus cell suspension was added to one well of a 48-well plate 
following with incubation at 37 degree and 5% CO2 for at least 30 min. Then 300 µL of 
culture medium was added to each well, which was then allowed to culture. After 
culturing, the plate was stained with crystal violet in methanol for imaging. 
3.3.10 Invasion assay 
Invasion assay was performed with a 24-well transwell plate (Corning). Three 
CTC samples, pure fibroblasts, one H1650 lung cancer cell line were seeded  at 1×105 
cells in 100 µl medium in the upper units of 8-µm-pore transwells coated with thin 
Matrigel. Fibroblast conditioned medium was added to the bottom well. After 24 hr 
incubation at 370C, cells in the upper chamber were removed and invaded cells on the 
lower surface of the porous membrane were fixed with methanol and stained with crystal 
violet. 
3.3.11 RNA extraction and RT-PCR 
CTCs cultured in well plates, primary tumor tissue samples as well as controls 
underwent RNA extraction using the RNeasy Mini Kit (Qiagen). Subsequently, cDNA 
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was made from the extracted RNA using the High Capacity cDNA Reverse Transcription 
Kit (Invitrogen). RNA samples isolated from primary tumors, CTCs, positive and 
negative controls were first converted to cDNA and then preamplified for marker genes 
of interest using Cells to Ct Kit (Ambion, Life Technologies) with some modification. 
Finally, preamplified cDNA samples were analyzed for mRNA expression of CK8, CK18, 
TTF1, EGFR, β-Catenin, CD45 (marker of WBCs), GAPDH and β-Actin (housekeeping 
gene) using TaqMan probes and Gene expression kit (Applied Biosystems) on ABI 
7900HT instrument (Applied Biosystems). Data was normalized to expression level of 
GAPDH or β-Actin and reported as fold change in expression level among different tested 
samples. 
3.3.12 TP53 sequencing 
cDNA from both primary tumors and corresponding CTC samples was PCR 
amplified with TP53 primers using Expand High Fidelity PCR System (Roche). The 
primer sets used in this study that flanked mutated TP53 fragments were as followings: 
TP53f1 5’>3’ GCTCCGGGGACACTTTGCGTTCG and TP53r1 5’>3’ 
GCAGCGCCTCACAACCTCCGTCAT, flanking bp 105 to 730 of TP53 gene (of NCBI 
ID NM_000546), and TP53hsF 5’>3’ CCCCCTCCTGGCCCCTGTCATCTTC and 
TP53hsR 5’>3’ TGTTGTTGGGCAGTGCTCGCTTAGTG, which flank the mutation 
hot-spot region of TP53 at bp 465 to 1136. The PCR products were characterized with gel 
electrophoresis and then purified using PCR Purification Kit (Qiagen). The concentration 
of the purified PCR products was measured and diluted for sequencing. The sequencing 
was performed at the University of Michigan sequencing core facility. 
3.3.13 DNA extraction from FFPE tumor tissue and sequencing  
Four regions of distinguishable cancer cells were marked in one FFPE slide 
stained with H&E reagent provided by Department of Pathology at University of 
Michigan Hospital. Fixed tissues were scraped from 4 identical slides and collected into 4 
different microtubes. Tissue DNA was extracted by the QIAamp DNA FFPE Tissue Kit 
(Qiagen). DNA of CTCs was extracted by the QIAamp DNA Mini Kit (Qiagen). 
Extracted DNA was PCR amplified using Expand High Fidelity PCR System (Roche). 
Table 4 summarizes the primer sets used in this study. The PCR program used is shown 
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in Figure 12. The PCR products were characterized with gel electrophoresis and then 
purified using PCR Purification Kit (Qiagen). The concentration of the purified PCR 
products was measured and diluted for sequencing. The sequencing was performed at the 
University of Michigan sequencing core facility. 
Primer pairs 
(5’à3’) 
Direction Region amplified Product length 
ttcaactctgtctccttcct F exon 5 248bp 
cagccctgtcgtctctccag R exon 5  
gcctctgattcctcactgat F exon 6 181bp 
ttaacccctcctcccagaga R exon 6  
aggcgcactggcctcatctt F exon 7 177bp 
tgtgcagggtggcaagtggc R exon 7  
ttccttactgcctcttgctt F exon 8 231bp 
aggcataactgcacccttgg R exon 8  
Table 4. DNA primer sets of exon 5, 6, 7 and 8 of TP53 gene. These sets are obtained 
from International Agency for Research on Cancer (IARC) TP53 database.  
 
 
Figure 12. PCR program used for amplifying exon 5, 6, 7 or 8 of TP53 gene. This 
program is obtained from IARC TP53 database. 
 
3.3.14 Next-generation sequencing 
RNA was extracted from CTCs and primary tumor and made into cDNA. Genes 
of interest were PCR amplified and sequenced using mixed primers from Qiagen 
comprehensive cancer panel for 124 cancer-related genes. Sequencing was performed 
with Illumina by core facility at the University of Michigan. Sequencing raw data was 
generated initially by Qiagen online informatics platform, and analyzed by 
Bioinformatics core facility. Called variants were filtered based on Fisher strand, allele 
frequency, mean read depth and mapping quality. All filtered variants were classified 
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based on their position relative to transcript. Following classification, any variant 
detected in a gene not targeted by the gene panel and present in 1K Genomes data set at a 
frequency greater than 1% was removed. Variants appeared in healthy controls and pure 
fibroblasts were removed. All filtered variants were finally validated by viewing in 
Genome Browser for accuracy. 
 
3.4 Results 
 
3.4.1 Patterning cancer cells and fibroblasts by the multi-inlet microfluidic device 
Figure 13 demonstrates that when applying vacuum at the outlet, the fluorescein 
bead solution is centered in the middle stream flanked by two plain streams on the sides. 
This shows that the multi-inlet microfluidic device can pattern cells in a side-by-side 
fashion. The device was tested with two cell lines, MCF7, a breast cancer cell line, and 
HMFs, human mammary fibroblasts. HMFs acted as the stromal cells in the tumor 
microenvironment. As shown in Figure 14, MCF7 cells are stained positive for CK (red) 
while HMFs are stained for cytoskeleton proteins specific to fibroblasts (green). MCF7 
cells tend to form spheroids because they are cultured in Matrigel, a 3D environment. 
These results demonstrate that cancer cells and stromal cells can be cultured in a 
microfluidic device in a controlled fashion. The patterned cells can be characterized with 
immunostaining to visualize their interaction.  
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Figure 13. The design of the multi-inlet microfluidic device. The device consists of 3 
inlets and 1 outlet. On the right, two fluorescent images demonstrate that if applying 
fluorescein beads in the middle inlet while adding plain solution in the other inlets, the 
beads will be confined in the middle of the laminar stream. 
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Figure 14. MCF7 cells and human mammary fibroblasts (HMF) are patterned and 
cultured in the multi-inlet microfluidic device. MCF7 cells are stained for CK (red). 
Fibroblasts are stained for intracellular cytoskeleton (green). 
 
 
3.4.2 Testing and optimizing in-situ CTC expansion with cancer cell lines 
The CTC culturing was performed in the CTC-capture device after CTCs were 
isolated. To determine the appropriate strategy for in-situ expansion of CTCs after 
isolation, small numbers of GFP-tagged A549 or H1650 cancer cells (100 cells) were 
spiked into 1mL of blood and flowed through the device. The numbers of cancer cells in 
the device on day 0 and day 7 were enumerated for comparison (Figure 15A). We 
observed that cells grown in the 3D co-culture environment exhibited the highest level of 
expansion, with an 8-fold (783± 248) increase by day 7 in culture. The 2D co-culture 
condition also facilitated a 3-fold (281± 52) cell expansion (p=0.049), using t-test 
compared to 3D co-culture condition. This condition was less efficient than the 3D co-
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culture. We did not observe significant expansion using a 3D or 2D mono culture 
environment (3D mono: 159± 133, p=0.035; 2D mono: 91± 48, p=0.018). Hence, a 3D 
co-culture environment was selected to be the optimal condition for in-situ on-chip CTC 
expansion in our system. The growth curves of A549-GFP cells in 3D co-culture 
condition over the 7 day period are shown in Figure 15B. During the initial 1-4 days, the 
cells grew slowly, perhaps adapting to the environment; however, by day 4, the cells 
exhibited significant growth. Figure 15C shows a scanning electron microscope (SEM) 
image of fibroblasts cultured in a mix of collagen and Matrigel beginning to spread in the 
microfluidic channel. A proliferation EdU assay (Invitrogen) was carried out to evaluate 
the proliferation potential of the cultured cancer cells on day 7 in device. The experiment 
was conducted according to protocol by the manufacture. Figure 15D demonstrates more 
than 90% of H1650-GFP cells are proliferating after being cultured for 7 days. The 
nucleus of the proliferating cells were stained as red. 
After 7 days of on-chip culture, cells were released from the device. 
Immunofluorescence staining was performed to validate the phenotype of the expanded 
cells. Figure 15E shows staining of expanded H1975 lung cancer cells with CK (red) and 
thyroid transcription factor 1 (TTF-1) (cyan) surrounded by GFP-labeled CAFs. The 
expression of TTF-1, a lung specific marker, was preserved in H1975 cells, known to 
express this marker [182], in the on-chip cultured environment.  
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Figure 15. Cancer cell expansion on chip. A. 100 H1650-GFP cells are captured and 
cultured in different environments (n=3 for each condition). B. 20-40 A549-GFP cells are 
captured and cultured in triplicate (indicated as Exp1, 2 and 3). The curves characterize 
the growth of the cancer cells. C. A scanning electron microscope (SEM) image is taken 
and showing fibroblasts in gel cultured on chip. D. EdU proliferation assay is performed 
on cancer cells co-cultured with fibroblasts on chip. Green: cancer cells; Red: nucleus of 
proliferating cells; E. Released H1975 lung cancer cells are cultured and IF stained in a 
well-plate after on-chip culture. TTF-1(cyan), DAPI (blue), Cytokeratin 7/8 (red), 
Fibroblasts-GFP (green). 
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3.4.3 Expansion and characterization of CTCs from early stage lung and esophageal 
cancer patients 
The CTC culturing strategy developed and optimized through cell line 
experiments was applied to test with clinical samples. Specifically, five mL of peripheral 
blood was drawn from lung and esophageal cancer patients. The blood was drawn before 
surgery under an IRB-approved protocol at the University of Michigan Hospital. Upon 
CTC isolation, one of the devices was IF stained with antibodies for enumerating CTCs 
on day 0. The remaining devices with cells were cultured with collagen I, Matrigel and 
GFP tagged CAFs for 7 days. Later, expanded patient CTCs were released and cultured 
up to 14 days in a well-plate. Nineteen lung cancer patient samples and fourteen 
esophageal cancer patients were tested for capture and expansion efficiency (sample C1-
C19 in Table 5, sample E1-E14 in Table 6). Figure 16A lists 19 lung cancer patient 
samples and 7 healthy controls with the number of CTCs captured on day 0 and on day 
14 after expansion. Figure 17A lists 14 esophageal cancer patients and 7 healthy controls 
with number of CTCs captured on day 0 and on day 14 after expansion. Fourteen of 19 
patient samples (73%) had successful expansion of isolated CTCs, 10 of 14 esophageal 
patient samples (71%) were successful whereas none of the CK positive cells from 
healthy controls demonstrated capability of expansion in culture.  
 
Patient  
Cancer 
Type Gender Age 
Tumor 
histology Stage 
TNM 
subtypes 
CTC count 
DAY0/1ml  
CTC count on 
DAY14 
C1 lung M 71 SCC IA T1bN0M0 6 87 
C2 lung M 72 SCC IIA T2aN1M0 2 16 
C3 lung F 50 AC IIB T2bN1M0 3 64 
C4 lung M 72 AC IIIA T3N1M0 4 118 
C5 lung F 74 AC IIA T2bN0M0 1 386 
C6 lung M 62 AC IB T2aN0M0 1 12 
C7 lung M 74 AC IIB T3N0M0 1 34 
C8 lung F 79 AC IA T1bN0M0 3 135 
C9 lung M 69 AC IIA T2aN1M0 9 125 
C10 lung F 71 AC IA T1bN0M0 3 65 
C11 lung M 86 AC IA T1aN0M0 4 42 
C12 lung F 70 SCC IIA T2bN0M0 11 70 
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C13 lung M 77 SCC IIIA T2aN2M0 1 92 
C14 lung M 63 SCC IB T2aN0M0 1 83 
C15 lung M 77 AC IA T1bN0M0 4 0 
C16 lung F 74 AC IIA T2bN0M0 3 0 
C17 lung F 53 SCC IIA T2aN1M0 4 0 
C18 lung M 93 SCC IA T1bN0M0 6 0 
C19 lung F 71 AC IA T1bN0M0 9 0 
Table 5. Demographic information of lung cancer patients for samples used for 
quantifying expansion of CTCs. 
 
Patient  
Cancer 
Type Gender Age 
Tumor 
histology Stage 
TNM 
subtypes 
CTC count 
DAY0/1ml  
CTC count on 
DAY14 
E1 esophagus M 64 AC IIA pT3N0 5 29 
E2 esophagus M 59 AC I pT1aN0 6 39 
E3 esophagus M 69 SCC I T1bN0M0 6 28 
E4 esophagus M 63 AC IIA ypT3N0 13 268 
E5 esophagus M 85 SCC IIA T3N0 10 88 
E6 esophagus M 51 AC IIIA ypT3N1 21 89 
E7 esophagus M 65 AC IIIB T3N2 4 44 
E8 esophagus M 62 AC IA T1bN0 1 152 
E9 esophagus M 55 AC IIIA T2N2 5 86 
E10 esophagus M 67 AC IIIA T2N2 4 19 
E11 esophagus M 61 AC IA pT1aN0 16 3 
E12 esophagus M 56 AC IV 
 
1 0 
E13 esophagus M 70 AC IIA pT3N0 3 4 
E14 esophagus M 76 AC IIA *ypT3N0 10 10 
Table 6. Demographic information of esophageal cancer patients for samples used 
for quantifying expansion of CTCs. 
 
An average of a 54-fold increase of lung CTCs (range 7-385 fold) and a 23-fold 
increase of esophageal CTCs (range 3-151 fold) was observed in patient samples. Figure 
16B and Figure 17B depicts fluorescence images of expanded patient CTCs in well-plates 
stained for CK 7/8 (red) along with GFP labeled fibroblasts. In one lung cancer patient 
(C23), the expanded CTCs were stained for TTF-1 (red) and found to be positive (Figure 
16C). RT-PCR analysis further confirmed that both the primary tumor and CTCs 
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demonstrated TTF-1 expression (Figure 19C). Additional staining for the proliferation 
marker Ki67 was demonstrated in the expanded CTCs as well (Figure 16C). One CTC 
sample was positive for epidermal growth factor receptor (EGFR) and pan-cytokeratin 
(Figure 16D). 
 
Figure 16. CTC expansion data from lung cancer patients. A. A growth chart shows 
the number of CTCs captured on day 0 (blue columns) and the number of CTCs on day 
14 (red columns) after expansion. CTCs are expanded successfully from 14 out of 19 
lung cancer patients. B. After expansion, CTCs are characterized in well-plates with 
CK7/8 (red) surrounded by GFP-fibroblasts. C. (left) CTCs from one patient sample (C23) 
are stained for TTF-1 (red). (right) CTCs from another patient sample are stained positive 
for Ki67 (purple). D. CTCs sorted out from fibroblasts are stained positive for EGFR 
(cyan) and pan-CK (red) and are negative for FITC suggesting elimination of GFP-
fibroblasts. 
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Figure 17. CTC expansion data from esophageal cancer patients. A. A growth chart 
compares the number of CTCs captured on day 0 (blue columns) and the number of 
CTCs on day 14 (red columns) after expansion. CTCs are expanded successfully from 10 
out of 14 esophageal cancer patients. B. After expansion, CTCs are characterized in well-
plates with CK7/8 (red) surrounded by GFP-fibroblasts. 
 
To test the tumorigenic properties of expanded CTCs in vitro, spheroid formation 
and invasion assay was performed. Expanded CTCs formed spheroids in three dimension 
culture whereas fibroblasts did not form spheroids (Figure 18A). One of the key features 
of tumor cells that are able to leave the primary tumor environment and enter the 
bloodstream is a capacity to invade [183]. We therefore assessed the invasion abilities of 
expanded CTCs using a Matrigel-based invasion assay. All three patient CTC samples, 
similar to H1650 lung cancer cells, demonstrated higher invasion capacity than GFP-
fibroblasts (Figure 18B). Fold increase of invaded CTCs compared to fibroblasts ranged 
from 1.5 to 13-fold. H1650 lung cancer cells exhibited a 2.5-fold increase compared to 
fibroblasts. The results of this section indicate that patient CTCs can be functionally 
characterized after a combined on-chip and off-chip culture strategy.  
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Figure 18. Functional studies of expanded lung CTCs. A. CTC spheroids are formed 
in a 3D gel assay. B. An invasion assay is performed with three CTC samples, 
fibroblasts-GFP and H1650 cells for 24 hours. Representative images of the transwell 
membrane are shown on the right. 
 
3.4.4 RNA profiling of expanded lung CTCs and matched primary tumors 
RNA was extracted from cultured lung CTCs and matched primary tumors. RT-
PCR was conducted to access the expression profile of the cells. This permitted direct 
comparison between CTCs and primary tumors. Figure 19 summarizes the normalized 
gene expression level of four cancer-related genes (CK8, CK18, TTF-1 and EGFR). CK8 
was overexpressed in both the tumor and CTCs of sample C23 compared to the healthy 
control (Figure 19A, Table 7). CK18 was highly expressed in sample C22 and C23 both 
in tumor and CTCs (Figure 19B). TTF-1 was expressed in both tumor and CTCs of 
sample C23 (Figure 19C). Importantly, TTF-1 expression was not observed in cells from 
the healthy control. We found higher EGFR expression in both tumors and CTCs from 
sample C22 and C23 compared with the healthy control (Figure 19D). Expression of 
EGFR in NSCLC is associated with frequent lymph node metastasis and chemo-
resistance [184]. In addition to these genes, we also characterized β-Catenin and CD45 
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expression in tumors and CTCs (Figure 19E and F) and found higher expression of β-
Catenin in patient samples. β-Catenin is involved in WNT signaling pathway and is 
important for cell survival [185]. CD45 was negative in all CTCs samples. In addition to 
GAPDH, the expression level of all of these genes was normalized to β-Actin and similar 
patterns were observed (Figure 20). 
Patient  Cancer Type Gender Age 
Tumor 
histology Stage TNM subtypes Characterizations performed 
C20 lung F 71 ADC IA T1bN0M0 mRNA expression 
C21 lung F 71 ADC IA T1bN0M0 mRNA expression 
C22 lung M 79 SCC IB T2aPL1N0M0 mRNA expression 
C23 lung F 85 ADC IIB T3N0M0 mRNA expression 
C24 lung M 77 SCC IIIA T2aN2M0 mRNA expression 
C25 lung M 68 SCC IA T1aN0M0 TP53 sequencing 
C26 lung M 80 SCC IIIA T1aN2M0 TP53 sequencing, Invasion assay 
C27 lung F 37 ADC IB T2aN0M0 Invasion assay 
C28 lung M 69 ADC IIIB T4N2M0 Invasion assay 
C29 lung F 72 LCC IIA T1aN1M0 TP53 sequencing 
C30 lung M 80 ADC IA T1bNxM0 TP53 sequencing 
C31 lung M 43 ADC IB T2aN0 M0 TP53 sequencing 
C32 lung M 69 SCC IA T1aN0M0 Next-generation sequencing 
C33 lung M 73 ADC IA T1bNxM0 Next-generation sequencing 
C34 lung M 69 ADC IIA T2aN1M0 Next-generation sequencing 
C35 lung F 79 ADC IA T1bN0M0 Next-generation sequencing 
C36 lung F 72 LCC IIA T1aN1M0 Next-generation sequencing 
C37 lung F 74 ADC IIA T2bN0M0 Next-generation sequencing 
C38 lung M 42 ADC IB T2aPL1N0M0 Next-generation sequencing 
C39 lung M 75 ADC IA T1aN0M0 Next-generation sequencing 
Table 7. Demographic information of lung cancer patients for samples used for 
molecular and functional characterizations. 
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Figure 19. mRNA expression level in primary tumor and CTCs. A to F. Cytokerain8 
(CK8), cytokeratin18 (CK18), TTF-1, EGFR, β-Catenin and CD45 gene expression levels  
are normalized to GAPDH. Tumor and CTCs mRNA from each patient sample are 
examined and compared. For example, “C20_T” represents patient C20 tumor (blue 
column) and “C20_CTC” represents patient C20 expanded CTCs (red column). The 
positive control is expanded H1650-GFP cells after initially spiking in blood with 100 
cells, labeled as “H1650 (co)” (green column). The negative control is one healthy 
control as “HC” (purple column). 
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Figure 20. mRNA expression normalized to β-Actin in primary tumor and CTCs. A 
to F. CK8, CK18, TTF-1, EGFR, β-Catenin and CD45 expression levels are in the same 
samples as in Figure 17. Here mRNA expression is normalized to β-Actin while Figure 
17 has mRNA expression normalized to GAPDH. 
 
3.4.5 TP53 sequencing in expanded lung CTCs and matched primary tumors 
TP53 is the most commonly mutated gene and is present in nearly 90% of 
squamous lung carcinomas and in nearly 50% of lung adenocarcinomas [137, 138]. Since 
TP53 mutation is an early event in lung tumorigenesis and believed to be preserved to 
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maintain the malignant phenotype during tumor progression and metastatic spread [186], 
we hypothesized that CTCs recovered and expanded from early stage lung cancer patients 
should preserve TP53 mutations present in the primary patient tumor.  RNA was 
extracted from matching primary tumors and ex-vivo cultured CTCs. And the tumor 
suppressor TP53 gene was sequenced. Among 15 lung cancer patient samples examined 
for the TP53 gene, 9 (60%) had mutations in TP53 gene. Five of the patient samples had 
matched mutations in primary tumors and CTCs (Figure 21, 22, Table 7). Figure 21 
shows two matched TP53 mutations between primary lung tumors and cultured CTCs. 
C25 had a G to A mutation in a non-coding region whereas C26 had G to A mutation in a 
coding region. However, in 3 patients, TP53 gene mutations were noted only in the 
primary tumors and not the matching CTCs, whereas in one patient, the mutation was 
seen only in the CTCs but not in the primary tumor. The remaining patient samples 
analyzed exhibited wild type TP53. TP53 mutations were absent from cancer associated 
GFP-fibroblasts as well as healthy controls, whose blood was run through the devices, 
co-cultured, released and processed for RNA extraction. These results demonstrate that 
tumor heterogeneity may exist in cells present in the primary tumor and in the circulation.  
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Figure 21. TP53 sequencing of lung cancer patient samples. One TP53 point mutation 
(G to A) is found matched between primary lung tumor and cultured CTCs in patient C25. 
Another matched point mutation (G to A) is observed between primary tumor and CTCs 
in patient C26. Healthy controls show no mutations. The table lists TP53 mutations found 
in CTCs and corresponding primary tumors in all 15 lung cancer patients tested. 
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Figure 22. Additional matched TP53 mutations between CTCs and tumors. Patient 
C29 has a T insertion. Patient C30 has an A to G mutation. Patient C31 has a G to C 
mutation. 
 
3.4.6 Investigating tumor heterogeneity 
To interrogate tumor heterogeneity and to examine if it can be reflected by CTCs, 
we sequenced four different regions of one primary tumor. FFPE tissue slides were 
obtained and four areas of distinct morphological features were identified. We collected 
tumor tissues separately from the areas and extracted DNA. The primer sets target exon 5, 
6, 7 and 8 of TP53 gene, which cover hotspot regions for mutations. We compared the 
mutations present in different areas of primary tumor with CTCs to find which area 
closely resembled CTCs. Figure 23 summarizes the sequencing results. Specifically, 
region 2, 3 and 4 harbored TP53 mutations on exon 5 and 7. While region 2 and 3 shared 
the same mutations (C176F and N239N), region 4 harbored additional mutations on exon 
5 (P151P and I162I). CTCs harbored the P151P and I162I mutations on exon 5 and the 
N239N on exon 7. Therefore, CTCs likely originated from region 2, 3 and 4. Figure 23B 
and C provide chromatograms of the mutations.  
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Figure 23. TP53 mutation status revealing tumor heterogeneity. A. This table 
summarizes TP53 mutations in CTCs and four different areas in corresponding primary 
tumor. “T1,2,3,4” refer to tumor region1,2,3 or 4 from the FFPE slide shown below the 
table. “X”: wild-type; “C176F”: codon 176 amino acid change from C to F due to 
missense mutation; “P151P”: codon151 silent mutation; “I162I”: codon 162 silent 
mutation; “N239N”: codon 239 silent mutation. B. Chromatograms of P151P and I162I 
seen in  CTCs and T4. C. Chromatograms of C176F observed only in T2,3 and 4 but not 
in CTCs, and N239N in CTCs, T2, T3 and T4. 
 
3.4.7 Next-generation sequencing of expanded lung CTCs and matched primary tumors 
To further explore the genomic markers CTCs might carry from tumors, next-
generation sequencing after targeted exon enrichment was performed with 8 paired 
primary tumor and CTC samples (sample C32-C39 in Table 7). Figure 24A shows 
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nonsynonymous (red) and synonymous (green) mutations with mutations in tumor in 
diamond shape and mutations in CTCs in square shape. Matched mutations between 
CTCs and primary tumor are highlighted with rectangles. Matched mutations were 
observed in 3 out of 8 paired CTC-tumor samples in CASP8, APC, TP53 and ERBB4 
genes. The locations of the mutations on the four genes and amino acid alterations are 
shown in Figure 24B. These results demonstrate that some of the key genes involved in 
cancer progression are manifested in CTCs and may relate to cancer metastasis.  
66 
	
 
Figure 24. Next-generation sequencing after targeted exon enrichment. A. 8 paired 
tumor and CTC samples (C32-C39) plus one healthy control and one pure fibroblasts-
GFP cell line are sequenced for 124 genes listed in the Qiagen Generead comprehensive 
cancer panel. Variants in each sample are identified by examining them in genome 
browser and confirmed by their absence in controls. B. Four matched mutations are listed 
with their locations on exons, base change and amino acid change. 
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3.5 Discussion 
 
3.5.1 The multi-inlet microfluidic device for cell patterning 
We demonstrate the ability to pattern different cell types by a multi-inlet 
microfluidic device. MCF7 cells and HMFs were spatially patterned in a straight channel. 
This platform can quantitatively measure the interactions between cancer cells and 
stromal cells in future studies. Microfluidics can mimic the physiological cues in the 
cellular environment through spatial and temporal control over gradients of soluble 
factors and cell-cell contacts in extracellular matrix [172]. It can also pattern cells to 
create the desired environmental stimuli for cell growth and proliferation [181, 187]. 
However, to culture cells in a microsystem, one needs to control the tiny environment 
surrounding the cells. Medium composition, shear stress, chemical gradients and 
temperature are important parameters to consider when designing the systems [188, 189]. 
Once the appropriate conditions are obtained, microfluidics provides a tailored, 
controlled environment for cellular studies.  
3.5.2 The microfluidic co-culture model for CTC expansion 
For over two decades, studies have shown that tumor cells shed from primary 
solid tumors, “CTCs” can be detected in the circulation [49, 190].  CTCs may serve as 
precursors to systemic metastases. Their biological and clinical significance is limited by 
inability to collect sufficient number of cells. Most studies to date examining biological 
relevance of CTCs have been carried out in animal models or patients with metastatic 
disease. Other efforts have been made to release CTCs using a DNA network or hydrogel 
but suffering cell loss and limited throughput [191, 192]. We present an in-situ 
microfluidic co-culturing model to expand captured CTCs on chip. This is achieved 
through creating a more physiological tumor microenvironment using a combination of 
collagen, Matrigel along with cancer associated fibroblasts on a miniaturized device 
consisted of channels of only 100 µm height. This enables better temporal and spatial 
control, reduction in material input, and enrichment of signaling molecules such as 
growth factors and cytokines [172]. This environment likely plays a key role in 
promoting CTC survival and expansion. 
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Ex vivo expansion of CTCs allowed us to characterize their phenotypes in 
multiple aspects. CTCs, but not fibroblasts alone, were able to form spheroids in 3D gel 
assays (Figure 18A). Additionally, only CTCs stained positive for CK and Ki67, 
demonstrating that CTCs can be functionally and phenotypically distinguished from 
fibroblasts (Figure 16). The expanded H1975 lung cancer cells as well as patient CTCs 
from sample C23 expressed TTF-1 while the cultured fibroblasts lacked expression 
suggesting tumor specific markers were preserved in our model (Figure 15E and 16C). 
This observation was confirmed at the gene expression level using RT-PCR to test 
several cancer-related genes in primary tumors and CTCs (Figure 19). mRNA expression 
was heterogeneous among different patients. In some patient samples, primary tumors 
and CTCs demonstrate higher CK8, CK18 and EGFR mRNA expression compared to the 
healthy control. Invasion assay demonstrated that CTCs possessed invasion capabilities 
and functional studies were feasible with expanded CTCs.  
More importantly, our studies enabled direct comparison of CTCs likely 
originating from only the primary tumor (as only patients with early stage cancer with no 
known metastasis were chosen for this study) in early stage patients. Matched TP53 
mutations were detected in patient tumors and CTCs but absent in fibroblasts and healthy 
controls. This is a strong indication that mutations in TP53 were preserved in CTCs, 
which might actively contribute to their ability to enable distant metastasis. We noted that 
5/15 lung cancer samples had matched TP53 mutation between CTCs and primary tumors, 
whereas 4 samples had unmatched mutations. We believe this may reflect the inherent 
tumor heterogeneity observed in lung cancer as in most solid tumors [193]. For patient 
C26, we sequenced 4 areas of the primary tumor and noted the concordance between 
TP53 mutations in 3 parts of the tumor and corresponding CTCs, which suggested that 
tumor heterogeneity likely played a role in CTC shedding (Figure 23). One patient C31, 
with matched TP53 mutations recurred within 3 months in the brain and died. Another 
patient C5 with a 385-fold increase in CTCs after expansion recurred in 3 months in the 
adrenal gland and died. The follow-up period in the other patients has not been long 
enough for recurrence data. Although a larger cohort is needed to investigate further the 
correlation between proliferation, mutational status of CTCs and survival, the presented 
data demonstrates feasibility of the approach.  
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Next-generation sequencing of 124 selected cancer-related genes further revealed 
that concordant mutations (APC, ERBB4, CASP8) existed in tumors and cultured CTCs in 
addition to TP53. These genes are related to key signaling pathways for cell growth or 
apoptosis, which collectively, may lead to tumor progression and metastasis. There are 
mutations unique to tumors but not in CTCs likely due to intra-tumor heterogeneity or 
variable abundance of specific mutations. On the other hand, there are mutations not seen 
in tumors but unique to CTCs such as NOTCH1 and BRCA2. Clinical significance of 
these mutations related to metastasis will need to be determined using larger cohorts for 
further investigation.  
In summary, we have shown ex vivo expansion of CTCs isolated from blood 
samples of early stage lung and esophageal cancer patients, including patients with Stage 
I disease. We have found concordant mutations involved in lung cancer progression in 
CTCs and primary tumors using an unbiased approach (NGS). Albeit, in some cases, we 
found mutations in genes in the primary tumors that were not noted in the CTCs and vice-
versa, which raised the possibility of tumor and CTC heterogeneity. Functionally, 
expanded CTCs were capable of invasion compared to fibroblasts. Additionally, patients 
whose CTCs exhibited the greatest capacity to expand ex vivo had earlier recurrence and 
died. Undoubtedly, this is an observation only in 2 patients and further studies are 
warranted. Finally, this microfluidic co-culture technique may open a new spectrum of 
opportunities for enriching early stage CTCs and aid in understanding the role of CTCs in 
metastasis. 
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Chapter 4 
CTC-derived xenograft from ex vivo expanded CTCs 
derived from a NSCLC patient 
 
 
 
4.1   Abstract 
 
A CTC-derived xenograft (CDX) presents a valuable model to interrogate cancer 
metastasis and perform drug susceptibility test, which will aid in personalized medicine 
and targeted therapy. Previous studies (to date only 4) demonstrated generating CDXs 
from patients with advanced breast, small-cell lung and colon cancers. Here we showed 
CTCs expanded from one early stage non-small cell lung cancer (NSCLC) patient 
successfully generated one xenograft model after 6 months.  H&E staining confirmed the 
CDX had the same histology as the primary cancer. Immunohistochemical staining 
further characterized the protein expression on the xenograft, which could be correlated 
with the RNA expression profile by RNA sequencing. Furthermore, we identified several 
genes enriched in the CTCs, xenograft and primary tumor. These genes are related to the 
epithelial-mesenchymal transition (EMT) and crosstalk between tumor and stromal cells 
in the tumor microenvironment.  
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4.2 Introduction 
While the exploration of innovative technologies for enhanced CTC isolation is 
always at the forefront of research, ex vivo culturing and in vivo xenograft models have 
gradually gained momentum in the field. During recent years, attempts have been made 
to culture CTCs in vitro or to generate CTC-derived xenografts (CDXs) from breast, 
prostate, colon and small-cell lung cancer patients of advanced stages [91, 97-99, 180, 
194].  Zhang et al. sorted a subset of breast CTCs to form cell lines and tumors in mice 
[97]. This model identified a novel gene signature associated with development of brain 
metastasis. Yu et al. successfully cultured breast CTCs followed by in vivo implantation 
and drug testing [180].  Cayrefourcq et al. established and characterized a cell line 
derived from colon CTCs, which also generated xenografts [99]. In the study by 
Hodgkinson et al., CTCs from SCLC patients were injected directly to mice [91]. 
Samples with CTC count >400/7.5ml successfully gave rise to tumors in mice in 2-4 
months. CDXs allow examining the tumorigenicity of CTCs as well as drug testing in 
vivo [195]. Our lab has reported ex vivo expansion of CTCs from early stage lung cancer 
patients using a microfluidic co-culture model [77]. In the present study, we utilized the 
culture strategy described in the previous paper and cultured CTCs from one early stage 
patient with lung squamous cell carcinoma. The expanded CTCs were injected into 
immune-compromised mice and generated a xenograft after 6 months. We then 
performed characterizations of the xenograft and compared it to the primary tumor. 
 
4.3 Methods 
4.3.1 CTC isolation and ex vivo expansion 
The detailed method can be found in our previous publication [77].  Briefly, 5 mL 
of the peripheral blood was drawn from the patient before surgery at the University of 
Michigan Hospital. The CTC-capture device was coated with EpCAM and CD44.  The 
blood was divided and run through two CTC-capture devices to isolate and culture the 
CTCs. Cancer associated fibroblasts mixed with collagen I and Matrigel was added to the 
devices. Then the cells were cultured on chip for 2 weeks before releasing them off the 
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devices. The released cells were further cultured in well-plates for two weeks and tested 
for spheroid formation capability and immunofluorescence staining to confirm the 
presence of CTCs.  
4.3.2 Generating the CTC-derived xenograft 
Cultured CTCs with cancer associated fibroblasts, around 50,000, were injected 
into one immune-compromised NOD scid gamma (NSG) mouse subcutaneously. The 
mouse was checked regularly for tumor formation. After harvesting the 1st generation 
xenograft, a small piece of the xenograft was subcutaneously implanted in two mice. The 
mice were checked periodically for tumor formation. 
4.3.3 H&E and immunohistochemical (IHC) staining 
The harvested xenograft tissue was fixed by 10% formalin and submitted to the 
In-vivo Animal Core Facility at the University of Michigan Medical School to perform 
H&E and IHC staining. The antibodies used are CD44 (BD Biosciences, clone G44-26), 
ALDH (BD Biosciences, clone 44/ALDH) and Pan-cytokeratin (Abcam). All the 
antibodies were tested with a negative and a positive control before staining the actual 
tumor samples. 
4.3.4 CTC isolation from mouse blood  
Prior to harvesting the xenograft, mouse blood was drawn in an EDTA tube. The 
blood was flowed through the CTC-capture device coated with EpCAM and CD44 for 
CTC isolation. After CTC capturing, the cells were stained for anti-human CK and anti-
mouse CD45. The device was scanned with an automated immunofluorescence 
microscope and the number of CTCs was counted.  
4.3.5 RNA sequencing 
RNA was extracted from cultured CTCs, the xenograft and the primary tumor by 
miRNeasy Mini Kit (Qiagen). The RNA concentration and quality was tested with 
Nanodrop at the Core facility. The extracted RNA was then diluted to the recommended 
concentrations and submitted for the next generation sequencing, which was performed 
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on the Illumina platform for 50 paired ends in the Core facility at the University of 
Michigan.  
4.3.6 RNA-seq data analysis 
Sequencing reads were mapped to a combination of human transcripts annotated 
in Gencode v19 and mouse transcripts annotated in Gencode vM2 [196]. Gene expression 
values were quantified using rSeq [197] in the unit of RPKM [198]. Heatmap and 
hierarchical clustering were generated using R function “heatmap.2” with Euclidean 
distance and complete link based on log-transformed gene expression values for genes 
with average expression value greater than 10 RPKM across the samples. We also 
performed the differential gene expression and compared the gene expression level of the 
cultured CTCs, xenograft and primary tumors with pure fibroblasts. The cutoff threshold 
of the differential gene expression analysis is 0.5. We specifically looked at 340 cancer-
associated genes and found some genes were enriched in the cultured CTCs, xenograft 
and primary tumor.   
 
4.4 Results 
4.4.1 Expanded lung CTCs generating a xenograft 
Five mL of peripheral blood from each of the four patients with early stage lung 
cancers was drawn before surgery at the University of Michigan Hospital. The blood 
samples were obtained under an IRB approved protocol, and run through the CTC-
capture devices to isolate and culture CTCs. The culturing method is described in our 
previous publication in which we have shown CTCs can be expanded in 10/14 early stage 
lung cancer patients [77]. The cultured CTCs were injected subcutaneously into immune-
compromised NGS mice. Only the CTCs from a patient with stage IIIA lung squamous 
cell carcinoma developed a xenograft after 6 months. Figure 25 is a schematic 
demonstration of the overall strategy of the study. After the first-generation xenograft 
was harvested, it was passaged to two new mice. The second-generation xenografts were 
developed after 4 months with a faster growth rate than the first-generation.  
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Figure 25. Overall strategy of generating a CDX from one NSCLC patient. After 
CTCs are isolated and culture ex vivo, they are injected into mice and generate a CDX. 
The 1st generation CDX is characterized and is compared to the primary tumor. It is 
further passaged to generate 2nd generation CDXs.  
 
4.4.2 Characterization of and comparison between the expanded CTCs, xenografts and 
primary tumor 
H&E staining revealed that the primary tumor was an invasive, poorly 
differentiated lung squamous cell carcinoma (Figure 26A). The first-generation and 
second-generation xenografts showed the same histology as the primary tumor (Figure 
26A). IHC staining revealed that the first-generation and second-generation xenografts 
were positive for pan-cytokeratin, CD44 and ALDH (Figure 26B and C).   
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Figure 26. H&E and IHC staining on the primary tumor and xenografts. A. H&E 
staining on the primary tumor, 1st and 2nd generation xenograft. The primary tumor is 
poorly differentiated SCC. B. IHC staining of pan-CK, CD44 and ALDH on the 1st 
generation xenograft. C. IHC staining of pan-CK, CD44 and ALDH on the 2nd generation 
xenograft.  
 
We also drew mouse blood and performed CTC isolation. Eight CTCs were 
identified in the first-generation mouse blood (Figure 27A). An average of 54 CTCs were 
isolated from blood of the second-generation mice (Figure 27B). These results 
demonstrate the xenograft model is reliably generated by the expanded CTCs, which 
suggests their tumorigenicity.  
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Figure 27. CTCs isolated from mouse blood. CTCs are stained for CK(red), 
CD45(green) and DAPI. A. CTCs from the 1st generation xenograft. B. CTCs from the 
2nd generation xenografts.  
 
4.4.3 Genomic analysis of the expanded CTCs, CTC derived xenograft and primary 
tumor 
To interrogate the biological pathways enabling the CTCs to grow in vitro and in 
vivo, we performed RNA sequencing on the expanded CTCs, the first-generation 
xenograft, the primary tumor, cancer associated fibroblasts and the normal mouse tissue. 
Normalized reads were analyzed by hierarchical clustering. Figure 28 shows the global 
gene expression profile of the samples. CTCs and fibroblasts are clustered closely 
because of the presence of fibroblasts in the expanded CTCs. The xenograft and primary 
tumor is clustered together despite there are some mouse genes expressed in the 
xenograft.  
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Figure 28. RNA expression analysis. Hierarchical clustering of the normal mouse tissue, 
the 1st generation xenograft, primary tumor, fibroblasts and CTCs.  
 
We then performed differential gene expression analysis on the CTCs, xenograft 
and primary tumor by comparing them with the fibroblasts. By examining 340 genes that 
are associated with cancer, we generated a list of genes that were enriched in the CTCs, 
xenograft and primary tumor (Figure 29).  Notably, KRT7, KRT8, KRT14, CD44 and 
ALDH1A2 were present in the xenograft, which corresponded to the IHC staining (Figure 
26B).  
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Figure 29. Genes shared between different samples. Venn diagram of the genes 
enriched in the CTCs, 1st generation xenograft and the primary tumor.  
 
Among the genes shared between the CTCs and primary tumor, MMP9 acts on 
remodelling extracellular matrix and aids in metastasis [199]. CSF1R is involved in the 
crosstalk between immune cells and cancer cells to induce cancer cell migration [173]. 
ID2 encodes a transcription factor which involves in inhibiting differentiation and 
enhancing tumor growth [200]. ROS1 encodes a receptor tyrosine kinase in NSCLC and 
its overexpression is correlated with poor prognosis [201].  
In addition, by examining the genes shared between the CTCs and xenograft, we 
found TGFB1, VIM and SPARC were expressed. TGFB1 and SPARC are involved in 
inter-communication between cancer and stromal cells [202, 203]. VIM encodes vimentin, 
an intermediate filament protein associated with epithelial-mesenchymal transition (EMT) 
and increased tumor growth [204]. SPARC is also correlated with EMT and tumor 
metastasis [205].  
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There are a number of genes shared between the primary tumor and the xenograft. 
Among them, KRT14, KRT8, MUC1 are epithelial cell markers whereas S100A4 is 
involved in EMT [206, 207]. ALDH1A2 is a cancer stem cell marker [208]. DCN is 
expressed by extracellular matrix of tumor stroma [209]. IL8 is a chemokine in tumor 
microenvironment to promote angiogenesis and metastasis [210]. MYD88 and NFKB1 are 
involved in inflammation in the tumor microenvironment [211, 212]. TP63, expressed by 
lung squamous cell carcinoma, is also seen in both the primary tumor and the xenograft 
[213]. PRDM1 is shown to localize in the nucleus of lung cancer cells [214]. Additionally, 
TM4SF1 is correlated with angiogenesis [215]. WNT2 is reported to correlate with lung 
carcinogenesis [216].   
Finally, among the genes shared between all three samples, a mix of epithelial 
genes (KRT7) and EMT genes (IGFBP4, TIMP1, ACTA2) were present [217-219]. MET 
is reported as an oncogene in lung cancer and its overexpression is related to 
tumorigenesis [220]. MET, CCDN1 and CD44 play roles in proteoglycans in cancer 
according to the KEGG pathway database. ANXA2 encodes Annexin A2, which is shown 
to be upregulated in lung SCC with lymph node metastasis [221]. High expression of 
RRM2 is found to be correlated with decreased response to gemcitabine of NSCLC 
patients and worse prognosis [222]. The overexpression of CCDN1 has been shown to 
relate to less differentiated lung cancer [223].  
 
4.5 Discussion 
In the present study, one CDX was generated by ex vivo expanded CTCs from an 
early stage lung cancer patient using a microfluidic co-culture model. The CDX exhibited 
the same histology and phenotypic features as the primary lung cancer. The first-
generation xenograft can be stably passaged and generated the second-generation 
xenografts, which allowed multiple analyses. We performed genomic analysis of the 
expanded CTCs, xenograft and primary tumor. Together, we observe the expression of 
TP63, which confirms the xenograft is derived from a poorly differentiated lung SCC. 
The CTCs, xenograft and primary tumor express epithelial (KRT7, 8, 14, 18 and MUC1), 
EMT markers (VIM, SPARC, S100A4, IGFBP4, TIMP1 and ACTA2), and stem cell 
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related genes (ALDH1A2 and WNT2) [224]. This suggests the cellular plasticity and EMT 
contributed significantly to cancer cell invasion and metastasis [225], and there are 
metastasis initiating niches enabling the xenograft to develop. 
Generating CTC-derived xenografts (CDXs) has been demonstrated by several 
groups using various technologies including flow cytometry sorting in breast cancer [97], 
depletion of white blood cells through RosetteSep Kit in breast[98], small-cell lung[91] 
and colon cancer[99] and CTC-iChip in breast cancer [180]. Compared to the previous 
technologies, our method achieves pre-enrichment of CTCs through ex vivo culturing 
before injecting to mice. Our findings are consistent with the previous work by Ting et al., 
in which they reported the presence of epithelial, EMT and stem cell markers in 
pancreatic CTCs through single-cell RNA-seq [226]. They also identified genes related to 
extracellular matrix (ECM) in pancreatic CTCs. Similarly, we find ECM genes such as 
MMP9, SPARC, DCN, TIMP1 and TGFB1, enriched in the CTCs, xenograft and primary 
tumor.  Additionally, genes such as CSF1R, IL8, MYD88, NFKB1 and TM4SF1, which 
are involved in the crosstalk between tumor and stromal cells, are upregulated in the 
samples. These genes suggest the important role tumor microenvironment plays in cancer 
development [173]. Targeting tumor stroma will contribute to preventing the spread of 
cancer cells to distant organs.  
Genes shared between the CTCs, xenograft or primary tumor may provide insight 
into the mechanism by which CTCs survive in circulation and ultimately grow in vitro 
and in vivo. Pathway analysis indicates Ras signaling is associated with the shared genes 
(p=0.004). Activated Ras proteins enhance tumor development through deregulation of 
proliferation, programmed cell death, angiogenesis and invasion [227]. The pathway 
shared between the xenograft and primary tumor is related to anti-apoptosis and cell 
survival (p=0.004). In particular, the activation of NF-κB protects cells against apoptosis 
[228]. We observe SPARC, TGFβ1 and VIM are shared between xenograft and CTCs but 
are absent in primary tumor. These CTC-specific genes may represent a small population 
of cells in the primary tumor, and the gene expression patterns may provide unique 
properties for CTCs to survive in the bloodstream and develop metastases. 
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The ability to generate xenograft is determined by the number of CTCs isolated 
and the potential of CTCs to grow ex vivo, which may correlate with tumor recurrence 
and prognosis. In this study, the cancer patient developed a pancreatic cancer two years 
after the resection of his primary lung tumor. This may correspond to the long time for 
the CTCs to grow in mice. Although this study is only limited to one xenograft, it is the 
first report on the generation of a NSCLC CDX from an early stage cancer patient. Our 
results from RNA-seq demonstrate that EMT and tumor microenvironment plays vital 
roles in cancer progression.  The CDX shows that CTCs from early stage NSCLC cancer 
patient are tumorigenic.  Potentially, CDXs can serve as platforms for testing targeted 
therapies and predicting patient outcome. Future studies need to include additional CDXs 
to interrogate metastatic properties of CTCs. 
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Chapter 5 
Demonstration of personalized therapeutics using CTCs: 
A case of expanded CTCs from ALK positive lung 
cancer patient carrying EML4-ALK rearrangement 
 
 
 
5.1 Abstract 
 
The emergence of liquid biopsy using circulating tumor cells (CTCs) as a resource to 
identify genomic alterations in cancer patients has brought up new opportunities to target 
specific driver mutations earlier in tumor progression. The presented study identified 
EML4-ALK gene rearrangement in expanded CTCs from one patient with ALK positive 
lung adenocarcinoma. A drug resistant mutation, L1196M on ALK gene was detected in 
expanded CTCs. Two ALK inhibitors, crizotinib and ceritinib, were tested on the 
cultured cells. We demonstrate that it is feasible to detect genetic aberrations in CTCs 
and perform drug screening. The findings suggest the clinical utility of CTCs for 
diagnosis and prognosis of non-small cell lung cancer (NSCLC) and the prospect of 
monitoring CTCs for effective therapeutic intervention.   
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5.2 Introduction 
   During recent years, collective efforts have been made to perform genomic 
profiling of NSCLC to reveal driver mutations [61, 138, 229]. Among all the genomic 
aberrations identified, mutations on the genes associated with receptor tyrosine kinase are 
important candidates for targeted therapies. For example, KRAS mutations occur in nearly 
30% of lung adenocarcinoma [61]. EGFR was found over-expressed in around 50% of 
NSCLC patients while mutations on EGFR were found in 10-20% of the patients of lung 
adenocarcinomas [61, 230, 231]. Gene rearrangement in anaplastic lymphoma kinase 
(ALK), ROS1 and RET was also noted in 3-5% of the patients [61]. Albeit the low 
occurrence, ALK arrangement, most likely with echinoderm microtubule-like protein 4 
(EML4), can be targeted in 60% of ALK-positive patients by a tyrosine kinase inhibitor 
(TKI), crizotinib, approved by FDA in 2011 [232-234]. However, most patients develop 
resistance to crizotinib within 1 to 2 years. The mutation G1269A induces stearic 
obstruction to crizotinib [235]. L1196M mutation, on the other hand, is a gatekeeper 
mutation that does not allow crizotinib to bind MET [235]. Recently, the second 
generation ALK inhibitor, ceritinib, was approved by FDA to combat with the acquired 
drug resistance to crizotinib [235].  
     With the rapid discoveries in sequencing as well as therapeutics, it is 
imperative to monitor the molecular evolution of tumors during treatment to provide 
effective therapies for patients. At the current time, the practice is to biopsy and rebiopsy 
at the time of radiological recurrence, which is invasive and not without risk.  ALK 
rearrangement is identified through fluorescence in situ hybridization (FISH) using a 
break-apart probe [236]. A separation of a red and a green signal indicates gene 
rearrangement. FISH test of tumor is the only approved method for detecting ALK 
rearrangement [237]. In recent years, EML4-ALK rearrangement has been revealed in 
circulating tumor cells (CTCs) from peripheral blood of NSCLC cancer patients [89, 143]. 
Sampling of CTCs, as “liquid biopsy”, is less invasive than solid biopsy; and permits 
real-time monitoring of cancer progression and prediction of treatment response [27, 70, 
140, 141, 238].  CTCs are cancer surrogates that have heterogeneous gene-expression 
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profiles and mirror genetic alterations in tumors [226]. Cultured CTCs or CTC-derived 
xenografts can serve as in vitro or in vivo models for drug testing [91, 180].  
    Here we present a study on one advanced stage lung cancer patient harboring 
EML4-ALK rearrangement in the tumor. CTCs were isolated from the peripheral blood of 
this patient during the initial and follow-up visit.  The cells were cultured through a 
microfluidic co-culture model reported in our previous study [77]. FISH analysis, ALK 
sequencing and drug testing was performed on the expanded CTCs.  
 
5.3 Methods 
 
5.3.1 CTC isolation and expansion 
Five mL of peripheral blood was drawn from the lung cancer patient into lavender 
EDTA tubes during the initial and follow-up visit. Blood was drawn at University of 
Michigan Hospital under an IRB-approved protocol. CTCs were captured by EpCAM 
and CD44 in three CTC-capture devices and cultured with cancer associated fibroblasts 
(CAFs) in the devices for two weeks and then outside devices for one month. The 
detailed procedure can be found in our previous study [77].  
5.3.2 FISH analysis on CTCs 
CTCs were spun onto polylysine-coated slides, and fixed with 1:3 acetic acid and 
methanol followed by air-drying. FISH test with two-color and break-apart probes was 
performed on the slides. An isolation of signals indicated ALK rearrangement and 
overlapping signals indicated non-rearranged gene.  
5.3.3 ALK sequencing 
DNA was extracted from expanded CTCs using the QIAamp DNA Mini Kit 
(Qiagen). Subsequently, DNA was PCR amplified with ALK exon 23 primers using 
Expand High Fidelity PCR System (Roche). The primer sets used were as followings: 
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ALK23F: GTAACTTTGTATCCTGTTCCTCCCAG and ALK23R: 
CACCCTGGGTTCCATCGAGGACTTG, flanking exon 23 of ALK gene [239]. The 
PCR products were characterized with gel electrophoresis and then purified using PCR 
Purification Kit (Qiagen). The concentration of the purified PCR products was measured 
and the PCR products were diluted for Sanger sequencing. The sequencing was 
performed at the University of Michigan sequencing core facility.  
5.3.4 Cell lines and reagents 
 We obtained the cancer-associated fibroblasts (CAFs) from Dr. Diane Simeone’s 
lab and A549, H3122 cell lines from Dr. David Beer’s lab both in the Department of 
Surgery at the University of Michigan Hospital. CAFs, A549 and H3122 cell lines were 
cultured in RPMI supplemented with 10% FBS and 1% Penicillin-Streptomycin. 
Crizotinib was purchased from Sigma-Aldrich, and ceritinib was purchased from 
Selleckchem. They were both reconstituted in DMSO for drug testing experiments in 
vitro.  
5.3.5 Drug testing 
CTCs, CAFs, A549, or H3122 were plated at a seeding density of 1000 cells/well 
on 96-well plates. Each drug concentration was tested in triplicate wells. A total of six 
different concentrations were tested for each drug. Cells were incubated with drugs for 
72hrs. After treatment, each well was incubated with Cell Proliferation Reagent WST-1 
assay (Roche) for 30min, 1hr, 1.5hr and 2hr. Absorbance was measured with Biotek-
Synergy Neo-plate Reader. The optimal duration of incubation was determined. The half 
maximal inhibitory concentration (IC50) was calculated with nonlinear regression model 
by Prism Graphpad. 
 
5.4 Results 
 
5.4.1 Detecting ALK rearrangement in expanded CTCs 
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One patient was presented with metastatic lung adenocarcinoma (AC). The biopsy 
specimen revealed ALK gene rearrangement by FISH. The patient was initially placed on 
crizotinib. A computerized tomography (CT) scan 6 months after crizotinib revealed near 
complete resolution of disease. However, a positron emission tomography (PET) scan at 
7 months showed progression in right hilum (Figure 30). Patient underwent a 
bronchoscopy and biopsy of the hilar mass, which revealed a secondary mutation 
L1196M. He was placed on ceritinib and his repeat scans revealed a decrease in the hilar 
mass.  
 
Figure 30. Tumor status of the metastatic lung cancer patient. A. CT scan at baseline 
and 6 months after crizotinib treatment. B. EML4-ALK gene rearrangement is detected in 
the primary tumor biopsy specimen by FISH.  
 
87 
	
In parallel, we isolated and cultured CTCs from his blood at the time of initial 
diagnosis and the follow-up visit. CTCs were cultured by a microfluidic co-culture model 
[77]. By the end of three-week ex vivo culture, most of the CAFs were sorted away by 
flow cytometry. The sorted CTCs were further cultured for one month. We performed 
FISH analysis on cultured CTCs and these CTCs revealed ALK rearrangements (Figure 
31). ALK rearrangement was noted in both the initial visit and the follow-up visit. Most 
of the CTCs had 3 copies of ALK and few cells with aneuploidy as well. However, there 
were several CTCs with rearrangement in one allele only, which was expected. 
 
Figure 31. ALK rearrangement observed in cultured CTCs. Cultured CTCs, during 
the initial and follow-up visit, are positive for EML4-ALK rearrangement by FISH. 
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5.4.2 Identifying L1196M mutation in expanded CTCs 
To examine the presence of L1196M mutation in cultured CTCs, we performed 
Sanger sequencing on exon 23 of ALK gene. CTCs didn’t carry the mutation in the initial 
visit but they harbored the mutation in the follow-up visit (Figure 32).   
 
Figure 32. DNA sequencing revealed L1196M mutation in cultured CTCs. During 
the 1st visit, the mutation is not present in CTCs. During the 2nd visit, a small number of 
CTCs harbor the mutation.  
 
5.4.3 Drug testing on expanded CTCs 
After verifying that the expanded CTCs harbored EML4-ALK rearrangement, we 
conducted in vitro experiments to test CTCs with crizotinib and ceritinib, which were 
applied to the patient. Since the CTCs were mixed with CAFs, we also conducted control 
experiments on pure CAFs, A549 and H3122 cell lines. A549 cell line serves as a 
resistant cell line while H3122, harboring the ALK rearrangement, is a sensitive cell line. 
The IC50s of various cells are shown in Figure 33. The IC50 of crizotinib against CTCs 
is 2268nM and IC50 of ceritinib is 1664nM. These values are higher than H3122 cell line 
mainly because of the presence of CAFs.  
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Figure 33. IC50s of cells treated with crizotinib and ceritinib. Cultured CTCs are 
compared with pure CAFs, a resistant cell line A549 and a sensitive cell line H3122. 
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5.5 Discussion  
  In the present study, we used a microfluidic co-culture method to isolate and 
culture CTCs for downstream genomic analysis and drug testing. We previously reported 
this co-culture model effectively isolated and expanded CTCs from early stage lung 
cancer patients [77].  Pailler et al. and Faugeroux et al. demonstrated detecting ALK 
rearrangement patterns by the ISET method to guide therapeutic decisions.  Detecting 
CTCs as “liquid biopsy” can complement conventional small-biopsy method, which may 
be limited by intra-tumoral heterogeneity. This is demonstrated by Abe et al. in a study to 
compare small biopsy with excision samples [139]. Although all 6 excision specimens 
were positive for ALK rearrangement, only 3 small biopsy samples were positive. 
Cultured CTCs serve as in vitro resources for mutation detection and drug testing to 
compensate for tumor biopsy specimens. 
The platform used to recover CTCs is a microfluidic device coated with 
antibodies against epithelial cell adhesion molecule (EpCAM) and CD44. EpCAM is 
expressed by epithelial tumor cells in many cancer types [24]. CD44 is reported to be 
found in 50% of the NSCLC samples [240]. Therefore, it was included in the capturing 
antibody cocktail to increase the yield of CTCs for subsequent culturing. We observe 
ALK rearrangement in the cultured CTCs of the ALK positive patient. Similarly as the 
other studies, this finding shows the clinical utility of CTCs as they carry concordant 
driver mutations as the tumor [89, 143]. Moreover, this mutation is preserved through 
culturing of the CTCs. Additionally, the drug resistant L1196M mutation on ALK is 
detected in the follow-up visit but not in the initial visit. This reflects the emerging 
dominance of the resistant mutation in the tumor tissue. More importantly, two FDA 
approved drugs crizotinib and ceritinib were tested on the cultured CTCs. The IC50 of 
crizotinib is higher than ceritinib (2268nM v 1664nM) as reported by others [235]. Due 
to the presence of CAFs, the IC50s of CTCs are higher than the H3122 cell line.  
However, the present study demonstrates the feasibility of performing drug testing on 
cultured CTCs. In the future, we will perform monoculture of CTCs to circumvent the 
limitation.   
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   In conclusion, our study demonstrates that the concordant ALK rearrangement is 
present in CTCs. Because of the expansion of the CTCs, drug testing was performed. Our 
finding is limited to one patient and the cultured CTCs are mixed with fibroblasts 
affecting the accuracy of the IC50s. Nonetheless, our results highlight that CTCs, as 
tumor surrogates, can be monitored during treatment; their genomic aberrations reflect 
the tumor genome in real time and can be potentially used for testing drug efficacy.  
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Chapter 6 
Conclusion 
 
 
6.1 Summary of research 
6.1.1 Isolation and ex vivo expansion of CTCs  
In this thesis, a CTC-capture device was developed (Chapter 2) and was further 
transformed to be a CTC-culture device (Chapter 3). CTCs were isolated from more than 
65% early stage lung and esophageal cancer patients. Among them, more than 70% were 
successfully cultured, which permitted a multitude of downstream molecular assays and 
functional studies. Since most of the patients enrolled in the study had localized diseases, 
we compared the genomic aberrations in CTCs with the matched primary tumors. The 
presence of concordant mutations confirmed the origin of CTCs and served as another 
validation of the study. Taken together, we demonstrate that CTCs can be isolated from 
early stage cancer patients therefore may aid in early cancer detection and diagnosis. 
Isolated and expanded CTCs can undergo immunostaining, RNA profiling and mutation 
analysis, which indicate the prognostic values of CTCs.  
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6.1.2 CTC-derived xenograft 
We observed the formation of one CTC-derived xenograft from a patient with 
early stage NSCLC (Chapter 4). This model demonstrated the tumorigenic potential of 
cultured CTCs and served as a proof-of-concept study to show the feasibility. The first-
generation xenograft took about 6 months to develop and the second-generation took 
around 4 months. RNA-sequencing revealed some of the important genes related to EMT 
and tumor microenvironment enriched in the xenograft, expanded CTCs and primary 
tumor. These gene-related pathways may play important roles in metastasis. Future 
studies will focus on generating and characterizing additional xenografts and interrogate 
the genes identified in this preliminary study.  
 
6.1.3 CTCs as biomarkers for personalized medicine 
In one ALK positive patient who had advanced lung adenocarcinoma, we 
identified the concordant EML4-ALK rearrangement in the cultured CTCs during the 
initial and the follow-up visit (Chapter 5). The emerged point mutation, L1196M, was 
detected in the follow-up visit when the patient experienced disease progression and 
developed resistance to crizotinib. We then tested the cultured CTCs with both the first-
line and second-line drug, crizotinib and ceritinib respectively. Although the IC50s of 
cultured CTCs were higher than the sensitive cancer cell line due to the presence of 
cancer associated fibroblasts, our results demonstrated CTCs mirrored the molecular 
evolution of tumors in real time during treatment. Future studies need to circumvent the 
limitation of co-culture by performing monoculture of CTCs, which will result in more 
accurate IC50 of applied therapeutics.  
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6.2 Limitations and future directions 
6.2.1 Optimizing the CTC isolation technologies and culturing conditions 
Microfluidics holds great promise for miniaturization and automation through 
handling small amount of materials and incorporating control systems. The next 
generation of microfluidic devices for CTC isolation will aim at achieving high detection 
efficiency, high cell viability, and high throughput. The CTC research field will also 
move from enumerating to exploring the biological and clinical significance of the cells. 
This will facilitate reliable detection of CTCs and incorporating CTC evaluation in 
routine clinical tests.  
The choices of downstream assays depend largely on the isolation technologies. 
For example, the CellSearch technology requires CTCs to be fixed prior isolation 
therefore the downstream analysis is limited to immunostaining. Other non-microfluidic 
technologies, such as ISET and HD-CTC assay, require RBC lysis and have low purity of 
isolated CTCs, which are also only suitable for immunostaining. On the other hand, the 
presented CTC-capture device handles unprocessed whole blood and exhibits high purity 
of isolated CTCs. Therefore, CTCs can be lysed on-chip directly and DNA/RNA can be 
collected for genomic analysis.  
The limitation of the CTC-capture device is that CTCs are bound to the device 
making functional studies and culturing challenging. In this thesis, we developed the 
strategy to expand CTCs directly on-chip initially followed by releasing the cells off chip. 
One of the drawbacks of this approach is that CTCs are co-cultured with CAFs, which 
can grow faster than cancer cells. Therefore, after cells are cultured on conventional well-
plates, CAFs may take over the culture after several weeks.  In the future, other 
microfluidic-based CTC isolation technologies can be used, such that the isolated CTCs 
are not bound to device. This will permit us to test other culturing methods such as the 
non-adherent, hypoxia culturing suggested by Yu et al. in breast cancer and Cayrefourcq 
et al. in colon cancer [99, 180]. 
Another limitation of the CTC-capture device is the low flow rate (1mL/hr) and 
small volume of blood it can process during one hour. It limits the yield of CTCs. The 
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future CTC-isolation device should be able to process larger volume of blood with a high 
flow rate. The CTC-iChip presents an example of combining the principle of 
immunomagnetic isolation with size based isolation, which processes blood samples with 
high-throughput [96]. And it can operate with either a positive selection or negative 
depletion mode. The positive selection mode permits CTC isolation with high specificity 
and purity therefore it is preferred when one wants to perform single-cell analysis or 
genomic analysis. On the other hand, the negative depletion mode isolates CTCs by 
depleting blood cells therefore it is not biased toward surface antigen expression. It can 
be ideal for CTC culturing when one is not sure which subpopulation of CTCs will 
eventually grow in vitro.   
Once a versatile microfluidic platform is developed for a specific type of cancer, 
the CTC culturing conditions should be optimized. Several key factors are worth 
considering including the medium composition (growth factors and conditioned medium), 
the incubator environment (hypoxia v normoxia) and culturing environment (2D v 3D).  
After a reliable culturing condition is determined, culturing CTCs can be included in pre-
clinical testing for drug susceptibility and responses to radiation therapy.  
 
6.2.2 CTCs in lung cancer 
Over the past decade, the advancement of technological innovation to isolate 
CTCs has allowed investigation of their clinical utility [168, 241]. We now understand 
that CTCs contain heterogeneous populations of both epithelial and mesenchymal 
phenotypes [242]. They harbor genetic alterations that correspond to primary tumor and 
metastatic sites. The discordant or unique mutations carried by CTCs that are absent in 
primary tumors reflect heterogeneity in primary tumor or small amount of subclonal 
populations, which are missed by conventional sequencing methods [243]. Together with 
cfDNA, CTCs have been shown as promising surrogates of tumor burden and activating 
mutations for targeted therapies. Specifically, CTCs offer opportunities to perform 
biological studies such as phenotypic and histological characterization, invasion & 
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migration assays, in vitro expansion, drug testing and deriving xenografts in animal 
models.  
Despite current advances in the field, CTC markers for lung cancer still fall short, 
when it comes to factoring  inter-tumor and intra-tumor heterogeneity [244]. We have 
seen this as discordance in markers between primary/metastatic cancers and CTC 
genotypes or phenotypes.  Additionally, there is still the problem of contaminating white 
blood cells, despite the emergence of several technologies that enable positive selection 
or negative depletion of leukocytes.  These factors along with a low yield in earlier stages 
of lung cancer handicap functional studies related to CTCs (for e.g. ability to detect 
metastasis initiation properties of lung CTCs as demonstrated in other cancers using 
EPISPOT [99, 245] or  invasion assay[77, 246]). In vivo studies of CTCs through 
generating CTC-derived xenografts generally require larger numbers of cells [91, 98], 
which are hard to obtain from early stage lung cancer patients; this is to some extent 
overcome by increasing blood throughput and sensitivity of isolation methods. Biology of 
metastasis as related to a cascade of events has vast implications in drug development. 
The study of CTCs opens up a window for understanding this process. One study found 
that the WNT2 gene was enriched in breast CTCs and another study  showed that genes 
involved in ECM  were highly expressed in pancreatic CTCs [226, 247]. These findings 
suggested that these genes and pathways could be targeted therapeutically to halt 
metastasis and likely improve survival. However, this type of study has not been done in 
lung cancer. Understanding metastasis initiating capabilities of CTCs in lung cancer will 
have a huge impact on providing specific adjuvant therapies targeted at these CTCs to 
reduce metastasis and improve survival. The next few years will allow us to further study 
these biological processes in depth and allow meaningful translation into the clinic. 
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